News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Data Highlights In Vivo Research and the Potential Mechanism of Action in Pancreatic and Prostate Cancers

CARLSBAD, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today highlights three posters presented during the American Association of Cancer Research (AACR) held in New Orleans from April 8-13, 2022.

Qualigen Chairman and CEO Michael Poirier commented, Our lead therapeutic program QN-302 may have the potential to ultimately treat multiple tumor types that are characterized by genomic quadruplexes (G4) which are overrepresented in numerous cancer-related genes. The findings reported in these posters illustrate promising in vivo anti-proliferative activity against pancreatic cancer and metastatic prostate cancer. We are encouraged by the results of these studies as we progress toward our goal to benefit the lives of cancer patients, and are on-track to initiate IND-enabling studies.

Pancreatic cancer remains a high unmet medical need with limited treatment options. According to the American Cancer Society, about 62,210 will be diagnosed with pancreatic cancer in the United States. in 2022, and more than 49,830 patients will die from the disease -- the highest mortality rate of all major cancers. For advanced disease, chemotherapy (sometimes along with a targeted drug therapy) may lengthen survival.1

Poster 2926, Structure-based design of quadruplex-binding small molecule compounds: The essential role of water molecules (Dr. Stephen Neidle) Crystal structures and computer modelling were utilized to characterize the details of the interactions of substituted naphthalene diimides targeted against human DNA quadruplexes, and in particular the role of water molecules in the binding site. It is concluded that information on conserved water molecules is important for drug design and has been used in the design of a current lead compound QN-302.

1 https://pancreatic.org/pancreatic-cancer/pancreatic-cancer-facts/

VIEW AACR POSTER

Session Category: ChemistrySession Title: Structural and Chemical BiologySession Date and Time: Tuesday Apr 12, 2022 9:00 AM - 12:30 PMLocation: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 40

Poster 4068, The potent quadruplex-binding compound QN-302 shows potent anti-proliferative activity in a prostate cancer cell panel and anti-tumor activity in anin vivomodel of metastatic prostate cancer (Dr. Stephen Neidle) demonstrated bioavailability and toleration at therapeutic doses in a prostate cancer cell line, PC3, which is derived from castration-resistant prostate cancer and is therefore relevant to the situation when hormone therapies are no longer effective. The in vivo study, which included the commonly used drug abiraterone, showed that QN-302 had statistically significant anti-tumor activity in this model (p=0.0008) relative to the controls, and was superior to abiraterone.VIEW AACR POSTER

Session Category: Experimental and Molecular TherapeuticsSession Title: New Chemotherapy AgentsSession Date and Time: Wednesday Apr 13, 2022 9:00 AM - 12:30 PMLocation: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 27

Poster 4069, The potent quadruplex-binding compound QN-302 shows anti-tumor activity in patient-derived in vivo models of pancreatic cancer (Dr. Stephen Neidle) outlined a study in which QN-302 displayed substantial anti-tumor activity in three patient-derived xenograft (PDX) models for pancreatic ductal adenocarcinoma (PDAC). Immunocompromised mice were subcutaneously implanted with PDX tumor fragments. Mice intravenously received either QN-302, a vehicle, or in some models, gemcitabine. In three of these models, significant changes in tumor growth were observed in those that received QN-302, together with good tolerance and bioavailability at therapeutic doses.

VIEW AACR POSTER

Session Category: Experimental and Molecular TherapeuticsSession Title: New Chemotherapy AgentsSession Date and Time: Wednesday Apr 13, 2022 9:00 AM - 12:30 PMLocation: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 27

QN-302 is the Companys genomic quadruplex (G4)-selective transcription inhibitor being developed as a potential treatment for PDAC, in addition to other tumors of high unmet clinical need. The abstracts accepted by AACR outline the potential binding to a quadruplex target for the compound, as well as significant anti-tumor activity in relevant animal models.

The AACR Conference, being held in New Orleans from April 8-13, 2022, is a focal point of the scientific cancer community where scientists, clinicians, other health care professionals, survivors, and patients review the latest advances in cancer science and medicine.

About Qualigen Therapeutics, Inc.

Qualigen Therapeutics, Inc. is a diversified life sciences company focused on developing treatments for adult and pediatric cancer, as well as maintaining and expanding its core FDA-cleared FastPack System, which has been used successfully in diagnostics for over 20 years. Our investigational QN-302 compound is a small molecule selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells; such binding could, by stabilizing the G4s against unwinding, help inhibit cancer cell proliferation. Our investigational QN-247 compound inhibits nucleolin, a key multi-functional regulatory protein that is overexpressed in cancer cells; QN-247 may thereby be able to inhibit the cells proliferation. QN-247 has shown promise in preclinical studies for the treatment of acute myeloid leukemia (AML). The investigational compounds within Qualigens RAS-F family of RAS oncogene protein-protein interaction inhibitor small molecules are believed to inhibit or block the binding of mutated RAS genes proteins to their effector proteins, thereby leaving the proteins from the mutated RAS unable to cause further harm. In theory, such mechanism of action may be effective in the treatment of about one quarter of all cancers, including certain forms of pancreatic, colorectal, and lung cancers. In addition to its oncology drug pipeline, Qualigen has an established diagnostics business which manufactures and distributes proprietary and highly accurate rapid blood testing systems to physician offices and small hospitals for the management of prostate cancer and other diseases and health conditions.

For more information about Qualigen Therapeutics, Inc., please visit http://www.qualigeninc.com.

Forward-Looking Statements

This news release contains forward-looking statements by Qualigen that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. These statements include those related to the Company's prospects and strategy for the development of therapeutic drug candidates. Actual events or results may differ from the Company's expectations. For example, there can be no assurance that the Company will successfully develop any drugs (including QN-302, QN-247 and RAS-F); that preclinical development of the Company's drugs (including QN-302, QN-247 and RAS-F, and the deprioritized infectious-disease drug candidate QN-165) will be completed on any projected timeline or will be successful; that any clinical trials will be approved to begin by or will proceed as contemplated by any projected timeline, or at all; that any future clinical trial data will be favorable or that such trials will confirm any improvements over other products or lack negative impacts; that any drugs will receive required regulatory approvals (or Fast Track designation or Orphan Drug status) or that they will be commercially successful; that patents will issue on the Company's owned and in-licensed patent applications; that such patents, if any, and the Company's currently owned and in-licensed patents would prevent competition; that the Company will be able to procure or earn sufficient working capital to complete the development, testing and launch of the Company's prospective therapeutic products (including QN-302, QN-247 and RAS-F, and QN-165); or that the Company will be able to maintain or expand market demand and/or market share for the Company's diagnostic products. The Company's stock price could be harmed if any of the events or trends contemplated by the forward-looking statements fails to occur or is delayed or if any actual future event otherwise differs from expectations. Additional information concerning these and other risk factors affecting the Company's business can be found in the Company's prior filings with the Securities and Exchange Commission, including its most recent Form 10-K, all of which are available at http://www.sec.gov.

The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this news release, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Contact:

Jules AbrahamJQA Partners, Inc.917-885-7378jabraham@jqapartners.com

Source: Qualigen Therapeutics, Inc.

AACR POSTER

Structural and Chemical Biology

AACR POSTER - CHART 1

New Chemotherapy Agents

AACR POSTER - CHART 2

Tumor Volumes for CTG-1128

AACR POSTER - CHART 3

Tumor Volumes for CTG-0952

AACR POSTER - CHART 4

Tumor Volumes for CTG-2184

See original here:
Qualigen Therapeutics Presents Three Posters of QN-302 at American Association of Cancer Research Conference - StreetInsider.com

Recommendation and review posted by Bethany Smith

On March 28, Gov. Ron DeSantis signed into law FloridasHouse Bill (HB) 1557, which disallows or limits schools from instructing children in certain sexual matters. The heart of the new law states, Classroom instruction by school personnel or third parties on sexual orientation or gender identity may not occur in kindergarten through grade 3 or in a manner that is not age-appropriate or developmentally appropriate for students in accordance with state standards.

The news was met in many quarters with histrionic outrage. The American Federation of Teachers presidentRandi Weingartengroused that the law will single out certain kids and families for derision and denigration. It is just wrong. Its intent is to divide our communities and make political hay, but it hurts children, hurts families and makes it hard for teachers to do their jobs.

Hardly. It simply doesnt allow teachers to discuss certain sexual identity issues with young children. Weingarten also inanely insisted that the law would shame LGBTQIA+people back into the closet by policing their identity.

Following the signing of the bill, a gay teacher in Parish, Florida, creepily bemoaned the fact that he canttalk about his love lifewith his kindergarteners anymore.

No one was more outraged than Joe Biden, however. On March 31 the day that some celebrate as the International Transgender Day of Visibility the president insisted that his administration is standing up for transgender Americansagainst hateful bills being passed at the state level and assured them, Youre so brave. You belong. And we have your back.

To show that Biden is really, really serious about his stance, his administrations Department of Health and Human Services raised the pink, white and blue striped Transgender flag at its D.C. headquarters.

Frighteningly, theDepartment of Justicegot into the act, issuing a press release on the Transgender Day of Visibility in which it proclaims that it sent a letter to all state attorneys general reminding them of federal constitutional and statutory provisions that protect transgender youth against discrimination, including when those youth seek gender-affirming care. The missive advises states that laws and policies that prevent individuals from receiving gender-affirming medical care may infringe on federal constitutional protections under the Equal Protection Clause and Due Process Clause of the Fourteenth Amendment. Not surprisingly, the word parent never once appeared in the document.

And California of course is doing what it can to maintain its reputation as the nations wackiest state. Democratic lawmakers areproposing to make California a havenfor transgender youth and their parents who are fleeing other states. State Senator Scott Wiener said apparently with a straight face They have a safe place to go if theyre threatened with prosecution. California will not be a party to this new wave ofdeadly L.G.B.T.Q. criminalization.

Its fascinating how a bill which doesnt allow for sexual identity issues to be discussed in grades k-3 can morph into deadly L.G.B.T.Q. criminalization. How could theBabylon Beepossibly satirize this?

In fact, California is actually the anti-Florida, and has done much do disempower parents. To wit:

AB 2119, which passed in September 2018, provides that the rights of minors and nonminors in foster careinclude the right to be involved in the development of case plan elements related to placement and gender affirming health care, with consideration of their gender identity. At the time, the American College of Pediatricians (ACPeds) filedtestimonyagainst the bill, urging legislators to reject it. Children with gender dysphoria believe they are not their biological sex, the groups March 2018 testimony read. A delusion is a fixed false belief. This bill proposes that foster children with gender dysphoria be socially affirmed into their delusion, and allowed to obtain experimental puberty blockers, and dangerous cross-sex hormones and surgery without parental consent.

In September 2021,AB 1184, a bill cosponsored by Planned Parenthood, became law. As the California Family Council explains, this diktat prohibits insurance companies from revealing to the policyholderthe sensitive services of anyone on their policy, including minor children (starting at age 12), even though the policy owner is financially responsible for the services. The term sensitive services refers to all health care services related to mental or behavioral health, sexual and reproductive health, sexually transmitted infections, substance use disorder, gender affirming care, etc. The bill doesnt detail the kindly sounding gender affirming care, but as defined by the University of California, San Francisco, itshormone therapy and a laundry list of surgeriesincluding vaginectomy, scrotoplasty, voice modification, etc., ad nauseam.

At a California Teachers Association conference in October 2021, teachers were advised on best practices for subverting parents, conservative communities and school principals on issues of gender identity and sexual orientation.

The Los Angeles Unified School Districts Office of Human Relations, Equity and Diversity hosted a 10-weekonline club for LGBT elementary schoolers, including children as young as four years oldin the fall of 2021.

And then theres Disney, which is in a state of rage over the passage of Floridas parental rights bill. As Christopher Rufo explains, Disney executives immediately organized a Reimagine Tomorrow Conversation Series meeting for its leaders and pledgedto mobilize the entire corporation in service of the LGBTQIA+ community. Those recruited included a black, queer, and trans person, a bi-romantic asexual, and the mother [of] one transgender child and one pansexual child, and announced ambitious new initiativesseeking to change everything from gender pronouns at the companys theme parks to the sexual orientation of background characters in the companys films.

Also, speaking in blunt terms, Disney executive producer Latoya Raveneau laid out the companys game plan. She said her team was implementing a not-at-all-secret gay agenda and regularly adding queerness to childrens programming. Production coordinator Allen Martsch, said his team has created a tracker to ensure that they are creating enough canonical trans characters, canonical asexual characters, [and] canonical bisexual characters. Corporate president Karey Burke said she supported having many, many, many LGBTQIA characters in our stories and reaffirmed the companys pledge to make at least 50 percent of its on-screen characters sexual and racial minorities.

The gender obsession has also extended to Disneys theme parks in Anaheim and Orlando. Diversity and inclusion manager Vivian Ware explains that Disney made the decision last year toeliminate all mentions of ladies, gentlemen, boys, and girlsin order to create that magical moment for children who do not identify with traditional gender roles.

It must be noted that Disney, whose name evokes warm and fuzzy images of Mickey, Donald, Goofy and Tinkerbell has been over the years the corporate equivalent of a heavy-breathing, sweaty guy in a trench coat lurking in a park. For example, a six-month investigation in 2014 revealed that at least35 Disney employees had been arrested for sex crimesagainst children, attempting to meet minors for sex, and possession of child pornography over the previous eight years. Additionally, other Disney employees were found to have exhibited an abiding interest in kiddie porn on the internet.

The transgender movement is cultish, and can have dire consequences. Brown University physician and researcher Lisa Littman released a study in 2018, which showed that rapid-onset gender dysphoria in young people may be driven in part by social and peer contagion. She stresses that nearly 70 percent of the teenagers were involved with a peer group in which at least one friend had identified as transgender. In some groups, the majority had done so. Nearly 65 percent of teens had spent an increased amount of time online and on social media, and parents reported that pro-transgender YouTube videos and blogs might have been influential. It is unclear how many of the kids who have joined the cult took it to the next level and actually engaged in hormone blockers and self-mutilation.

In reality, Sex is determined at conceptionby our DNA and is stamped into every cell of our bodies, asserts Dr. Michelle Cretella, President of the American College of Pediatricians. Human sexuality is binary. You either have a normal Y chromosome and develop into a male, or you dont, and you will develop into a female. There are at least6,500 genetic differences between men and women.Hormones and surgery cannot change this. Nor can Disney, Joe Biden, Randi Weingarten or any other gender zealot.

The good news is that a poll taken in late March reveals that when Americans are presented with the actual language of the new Florida law,61% are in favor, while just 26% oppose. Importantly, there is bipartisan support. Republicans are in favor by a 70%-23% margin, while Democrats support it by 55%-29%. And, indeed states are acting.Georgia lawmakers have alreadyintroduceda bill that would similarly restrict classroom discussion of sexual orientation or gender identity, and other bills targeting related content in schools arependingin Indiana, Tennessee, Oklahoma and Kansas. Hopefully, the other 44 states will get aboard soon.

First published at: For Kids and Country.

Photo by skyseeker, Attribution 2.0 Generic (CC BY 2.0).

Visit link:
News - The Sandstorm: The Gender Cultists Meet Resistance - The Heartland Institute

Recommendation and review posted by Bethany Smith

Country

United States of AmericaUS Virgin IslandsUnited States Minor Outlying IslandsCanadaMexico, United Mexican StatesBahamas, Commonwealth of theCuba, Republic ofDominican RepublicHaiti, Republic ofJamaicaAfghanistanAlbania, People's Socialist Republic ofAlgeria, People's Democratic Republic ofAmerican SamoaAndorra, Principality ofAngola, Republic ofAnguillaAntarctica (the territory South of 60 deg S)Antigua and BarbudaArgentina, Argentine RepublicArmeniaArubaAustralia, Commonwealth ofAustria, Republic ofAzerbaijan, Republic ofBahrain, Kingdom ofBangladesh, People's Republic ofBarbadosBelarusBelgium, Kingdom ofBelizeBenin, People's Republic ofBermudaBhutan, Kingdom ofBolivia, Republic ofBosnia and HerzegovinaBotswana, Republic ofBouvet Island (Bouvetoya)Brazil, Federative Republic ofBritish Indian Ocean Territory (Chagos Archipelago)British Virgin IslandsBrunei DarussalamBulgaria, People's Republic ofBurkina FasoBurundi, Republic ofCambodia, Kingdom ofCameroon, United Republic ofCape Verde, Republic ofCayman IslandsCentral African RepublicChad, Republic ofChile, Republic ofChina, People's Republic ofChristmas IslandCocos (Keeling) IslandsColombia, Republic ofComoros, Union of theCongo, Democratic Republic ofCongo, People's Republic ofCook IslandsCosta Rica, Republic ofCote D'Ivoire, Ivory Coast, Republic of theCyprus, Republic ofCzech RepublicDenmark, Kingdom ofDjibouti, Republic ofDominica, Commonwealth ofEcuador, Republic ofEgypt, Arab Republic ofEl Salvador, Republic ofEquatorial Guinea, Republic ofEritreaEstoniaEthiopiaFaeroe IslandsFalkland Islands (Malvinas)Fiji, Republic of the Fiji IslandsFinland, Republic ofFrance, French RepublicFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabon, Gabonese RepublicGambia, Republic of theGeorgiaGermanyGhana, Republic ofGibraltarGreece, Hellenic RepublicGreenlandGrenadaGuadaloupeGuamGuatemala, Republic ofGuinea, RevolutionaryPeople's Rep'c ofGuinea-Bissau, Republic ofGuyana, Republic ofHeard and McDonald IslandsHoly See (Vatican City State)Honduras, Republic ofHong Kong, Special Administrative Region of ChinaHrvatska (Croatia)Hungary, Hungarian People's RepublicIceland, Republic ofIndia, Republic ofIndonesia, Republic ofIran, Islamic Republic ofIraq, Republic ofIrelandIsrael, State ofItaly, Italian RepublicJapanJordan, Hashemite Kingdom ofKazakhstan, Republic ofKenya, Republic ofKiribati, Republic ofKorea, Democratic People's Republic ofKorea, Republic ofKuwait, State ofKyrgyz RepublicLao People's Democratic RepublicLatviaLebanon, Lebanese RepublicLesotho, Kingdom ofLiberia, Republic ofLibyan Arab JamahiriyaLiechtenstein, Principality ofLithuaniaLuxembourg, Grand Duchy ofMacao, Special Administrative Region of ChinaMacedonia, the former Yugoslav Republic ofMadagascar, Republic ofMalawi, Republic ofMalaysiaMaldives, Republic ofMali, Republic ofMalta, Republic ofMarshall IslandsMartiniqueMauritania, Islamic Republic ofMauritiusMayotteMicronesia, Federated States ofMoldova, Republic ofMonaco, Principality ofMongolia, Mongolian People's RepublicMontserratMorocco, Kingdom ofMozambique, People's Republic ofMyanmarNamibiaNauru, Republic ofNepal, Kingdom ofNetherlands AntillesNetherlands, Kingdom of theNew CaledoniaNew ZealandNicaragua, Republic ofNiger, Republic of theNigeria, Federal Republic ofNiue, Republic ofNorfolk IslandNorthern Mariana IslandsNorway, Kingdom ofOman, Sultanate ofPakistan, Islamic Republic ofPalauPalestinian Territory, OccupiedPanama, Republic ofPapua New GuineaParaguay, Republic ofPeru, Republic ofPhilippines, Republic of thePitcairn IslandPoland, Polish People's RepublicPortugal, Portuguese RepublicPuerto RicoQatar, State ofReunionRomania, Socialist Republic ofRussian FederationRwanda, Rwandese RepublicSamoa, Independent State ofSan Marino, Republic ofSao Tome and Principe, Democratic Republic ofSaudi Arabia, Kingdom ofSenegal, Republic ofSerbia and MontenegroSeychelles, Republic ofSierra Leone, Republic ofSingapore, Republic ofSlovakia (Slovak Republic)SloveniaSolomon IslandsSomalia, Somali RepublicSouth Africa, Republic ofSouth Georgia and the South Sandwich IslandsSpain, Spanish StateSri Lanka, Democratic Socialist Republic ofSt. HelenaSt. Kitts and NevisSt. LuciaSt. Pierre and MiquelonSt. Vincent and the GrenadinesSudan, Democratic Republic of theSuriname, Republic ofSvalbard & Jan Mayen IslandsSwaziland, Kingdom ofSweden, Kingdom ofSwitzerland, Swiss ConfederationSyrian Arab RepublicTaiwan, Province of ChinaTajikistanTanzania, United Republic ofThailand, Kingdom ofTimor-Leste, Democratic Republic ofTogo, Togolese RepublicTokelau (Tokelau Islands)Tonga, Kingdom ofTrinidad and Tobago, Republic ofTunisia, Republic ofTurkey, Republic ofTurkmenistanTurks and Caicos IslandsTuvaluUganda, Republic ofUkraineUnited Arab EmiratesUnited Kingdom of Great Britain & N. IrelandUruguay, Eastern Republic ofUzbekistanVanuatuVenezuela, Bolivarian Republic ofViet Nam, Socialist Republic ofWallis and Futuna IslandsWestern SaharaYemenZambia, Republic ofZimbabwe

Go here to see the original:
Global Genetic Testing Markets Forecasts, Applications and Technologies Research Report 2022 - ResearchAndMarkets.com - Galveston County Daily News

Recommendation and review posted by Bethany Smith

The UAB Cardiogenomics Clinic provides genetic testing and counseling for a gene variant associated with a risk of heart failure and death.

Researchers believe that the presence of the Val122Ile genetic variant in African Americans is believed to predispose them to the development of transthyretin amyloidosis, which can lead to higher risk of heart failure.A new study published in the Journal of the American Medical Association led by researchers from the University of Alabama at Birmingham Marnix E. Heersink School of Medicine found that being a carrier of a genetic variation known as Val122Ile in the transthyretin, or TTR gene, was significantly associated with an increased risk of heart failure and death. Research shows that this Val122Ile variation is more commonly seen among individuals of African ancestry.

Transthyretin protein is produced by the liver and helps circulate vitamin A and thyroxine through the body. This genetic variation causes misfolding of the transthyretin protein leading to hereditary transthyretin amyloidosis, a condition characterized by the buildup of abnormal deposits of a protein in the bodys organs and tissues. As buildup increases over time, the heart may become stiff, leading to cardiomyopathy, a disease of the heart muscle that makes it difficult to pump blood through the heart.

For this study, UAB researchers Vibhu Parcha, M.D., and Pankaj Arora, M.D., looked at this genetic variation in a cohort of 7,500 Black individuals living in the United States.

The TTR Val122Ile genetic variant is unfortunately more common among those of African ancestry with nearly three out of 100 individuals carrying the genetic variation, said Parcha, a clinical research fellow in the UAB Cardiogenomics Clinic and the UAB Division of Cardiovascular Disease.

Parcha says the presence of the Val122Ile genetic variant in African Americans is believed to predispose them to the development of transthyretin amyloidosis.

We wanted to examine whether carrying this genetic variant will lead to a higher risk of new-onset heart failure, death due to heart failure, cardiovascular causes or any other causes, Parcha said.

(Left) Vibhu Parcha, M.D., clinical research fellow in the UAB Cardiogenomics Clinic and the UAB Division of Cardiovascular Disease. (Right) Pankaj Arora, M.D., an associate professor in the Division of Cardiovascular Disease and director of the UAB Cardiogenomics Clinic.In this study, researchers analyzed participants from the REasons for Geographic and Racial Differences in Stroke study living in the United States without baseline heart failure. Among 7,514 Black participants, the population frequency of the TTR Val122Ile variant was 3.1 percent. Over a median follow-up of 10.9 years, Val122Ile variant carriers had a higher risk of incident heart failure compared with non-carriers. Over a median follow-up of 11.6 years, Val122Ile variant carriers had a higher risk of mortality compared with non-carriers. Overall researchers found that those with the TTR Val122Ile variant had a 2.5-fold higher risk of heart failure and a 40 percent higher risk of death from any reason.

Among those with the pathogenic TTR Val122Ile genetic variation, the heart may gradually become unable to function correctly, which will lead to heart failure and ultimately death, said Arora, an associate professor in the Division of Cardiovascular Disease and director of the UAB Cardiogenomics Clinic. However, the true probability of genetic variation being expressed in all those with the variant is not known, and further work is needed to understand this. The good news is that there are several new treatments approved or awaiting approval for this hereditary heart disease.

Medical facilities like the UAB Cardiogenomics Clinic provide genetic testing for this variant. At the clinic, those who carry this variant will have access to comprehensive genetic counseling and assessment of their heart structure and function.

Those with the variant may be eligible for getting access to evidence-based therapies that improve their heart health and improve their long-term outcomes, Arora said. It is also important to identify any family members who may have the genetic variation as they will benefit from early diagnosis and access to medical therapies that improve their health.

Learn more about the UAB Cardiogenomics Clinic here.

Original post:
Genetic variation common among Black individuals is associated with higher risk of heart failure and death - University of Alabama at Birmingham

Recommendation and review posted by Bethany Smith

This Direct-to-Consumer (DTC) Genetic Testing Market report provides a comprehensive overview of important aspects that will drive market growth such as Market drivers, restraints, prospects, opportunities, restraints, current trends, and technical and industrial advancements. The detailed industry study, industry sector development and improvement, and new product launches presented in this Direct-to-Consumer (DTC) Genetic Testing market report are of tremendous help to the significant new commercial entrants entering the market. This Direct-to-Consumer (DTC) Genetic Testing market report carries out an attentive market assessment and offers an expert analysis of the market considering the market development the current market situation and future projections. This Direct-to-Consumer (DTC) Genetic Testing market report study further highlights the market driving factors, market overview, industry volume, and market share. Since this Direct-to-Consumer (DTC) Genetic Testing market report offers an effective market strategy, key players can reap huge profits by making the right investments in the market. As this Direct-to-Consumer (DTC) Genetic Testing Market report depicts the ever-changing needs of consumers, sellers, and buyers across different regions, it becomes easy to target specific products and attain significant revenue in the global market.

The report includes company profiles of almost all the major players operating in the Direct-to-Consumer (DTC) Genetic Testing market. The Company Profiles section provides valuable analysis of key market players strengths and weaknesses, business developments, recent advances, mergers and acquisitions, expansion plans, global footprint, market presence, and product portfolios. This information can be used by players and other market participants to maximize their profitability and streamline their business strategies. Our competitive analysis also includes key insights to help new entrants identify barriers to entry and assess the level of competitiveness in the Direct-to-Consumer (DTC) Genetic Testing market.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-direct-to-consumer-dtc-genetic-testing-market&Somesh=

The direct-to-consumer (DTC) genetic testing market is expected to witness market growth at a rate of 12.15% in the forecast period of 2021 to 2028. Data Bridge Market Research report on direct-to-consumer (DTC) genetic testing market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the markets growth. The rise in the incidences ofgenetic disordersglobally is escalating the growth of direct-to-consumer (DTC) genetic testing market.

The report provides an excellent overview of the main macroeconomic factors having a significant impact on the growth of the Direct-to-Consumer (DTC) Genetic Testing market. It also provides the absolute dollar opportunity analysis which can be crucial in identifying revenue generation and sales increasing opportunities in the Direct-to-Consumer (DTC) Genetic Testing market. Market players can use the qualitative and quantitative analysis provided in the report to get a good understanding of the Direct-to-Consumer (DTC) Genetic Testing market and make strong strides in the industry in terms of growth. The overall Direct-to-Consumer (DTC) Genetic Testing market size and that of each segment studied in the report are accurately calculated based on various factors.

Key Players Mentioned in the Direct-to-Consumer (DTC) Genetic Testing Market Research Report:

The major players covered in the direct-to-consumer (DTC) genetic testing market report are EasyDNA, Ancestry, 23andMe, Inc., Colour Genomics, Inc., Genesis HealthCare, Full Genomes Corporation, Inc., Helix OpCo LLC, IDENTIGENE, LLC, Living DNA Ltd, Mapmygenome, Pathway Genomics, Gene by Gene, Ltd., MyHeritage Ltd., 10X Genomics, Dante Labs, Inc., 24Genetics, LabCorp, Myriad Genetics, Inc., Quest Diagnostics Incorporated and Abacus Diagnostica Oy among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Read Detailed Index of full Research Study @https://www.databridgemarketresearch.com/reports/global-direct-to-consumer-dtc-genetic-testing-market?Somesh=

Direct-to-Consumer (DTC) Genetic Testing Market Segmentations:

Geographic Segment Covered in the Report:

The Direct-to-Consumer (DTC) Genetic Testing report provides information about the market area, which is further subdivided into sub-regions and countries/regions. In addition to the market share in each country and sub-region, this chapter of this report also contains information on profit opportunities. This chapter of the report mentions the market share and growth rate of each region, country, and sub-region during the estimated period.

The market research analysis further talks about the forces of the industry to shape the market. Important drivers and end-user expectations are also discussed in the Direct-to-Consumer (DTC) Genetic Testing market report to gain solutions. The forecast of related revenue is also made in the report. The primary purpose of the report is to categorize opportunities. It also explains what business models are being used, what the current level of success is, what is the market share and size, and what is the current level of competition in the market. It also sheds light on the functional areas of the company. This Direct-to-Consumer (DTC) Genetic Testing market report also shows how dead stock affects profits and how product losses can be eliminated. With the business tactics provided here, it is possible to experience accelerated growth of your business. It also provides a clear picture of how different business sectors are experiencing the negative impact of COVID-19.

New Business Strategies, Challenges & Policies are mentioned in Table of Content, Request TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-direct-to-consumer-dtc-genetic-testing-market&Somesh=

Key Benefits for Industry Participants & Stakeholders:

Key Questions Covered in this Report?

Make an Enquiry before [emailprotected]https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-direct-to-consumer-dtc-genetic-testing-market&Somesh=

Top Trending Reports:

https://www.marketwatch.com/press-release/passenger-car-sensors-market-analytical-study-growth-strategies-size-product-type-end-user-competitive-analysis-and-forecast-by-2028-2022-04-13

https://www.marketwatch.com/press-release/network-automation-market-analytical-study-growth-strategies-size-product-type-end-user-competitive-analysis-and-forecast-by-2028-2022-04-13

https://www.marketwatch.com/press-release/network-management-systems-marketglobal-industry-share-size-growth-demands-revenue-top-leaders-and-forecast-by-2029-2022-04-13

https://www.marketwatch.com/press-release/network-security-market-size-industry-growth-competitive-landscape-recent-developments-regional-outlook-and-forecast-by-2028-2022-04-13

https://www.marketwatch.com/press-release/network-security-software-market-size-trends-analysis-report-by-product-by-end-use-competitive-landscape-and-recent-developments-by-2028-2022-04-13

https://www.marketwatch.com/press-release/network-telemetry-market-new-business-opportunities-growth-rate-development-trend-and-feasibility-studies-by-2029-2022-04-13

https://www.marketwatch.com/press-release/night-vision-system-nvs-vehicle-intelligence-system-market-analysis-emerging-technologies-industry-trends-business-insights-size-segments-and-forecast-by-2029-2022-04-13

About Data Bridge Market Research, Private Ltd

Data Bridge Market ResearchPvtLtdis a multinational managementconsultingfirm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.

Data Bridge Market Research is a result of sheer wisdom and practice that was conceived and built-in Pune in the year 2015. The company came into existence from the healthcare department with far fewer employees intending to cover the whole market while providing the best class analysis. Later, the company widened its departments, as well as expands their reach by opening a new office in Gurugram location in the year 2018, where a team of highly qualified personnel joins hands for the growth of the company. Even in the tough times of COVID-19 where the Virus slowed down everything around the world, the dedicated Team of Data Bridge Market Research worked round the clock to provide quality and support to our client base, which also tells about the excellence in our sleeve.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries includes

Contact Us

US: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email [emailprotected]

Read the original here:
Direct-to-Consumer (DTC) Genetic Testing Market Trends Analysis, Top Manufacturers, Shares, Growth Opportunities, Statistics and Forecast by 2028 ...

Recommendation and review posted by Bethany Smith

11 April 2022

The world's first bedside genetic test that could prevent babies from losing their hearing has proven successful according to the NHS.

The 26 minutes genetic test, called the Genedrive MT-RNR1 test, can identify babies who carry a particular genetic variant that could make them permanently deaf when treated with a common emergency antibiotic. Babies admitted to intensive care with a suspected infection are routinely given an antibiotic called gentamicin within 60 minutes, which is used to safely treat approximately 100,000 babies a year. However, one in 500 babies carry the genetic variant that can make it cause permanent hearing loss. Researchers expect that the new genetic test could prevent permanent hearing loss in 180 babies in England every year.

'I am absolutely thrilled with the success of the study, and that this testing is now going to be used in three of our Trust's Neonatal Intensive Care Units it's actually going to make a real difference so babies are not going to lose their hearing for a preventable reason,' said one of the study's co-authors Professor William Newman, from the University of Manchester, and who led the initial Pharmacogenetics to Avoid Loss of Hearing (PALoH) study. 'The trial demonstrated that you can deploy rapid genetic testing in a clinical setting, and that the tests can be carried out within the 'golden hour' when severely unwell babies should be treated with antibiotics.'

In the current clinical trial, published in JAMA Pediatrics, researchers at two hospitals in Manchester used the Genedrive MT-RNR1 test to screen 424 newborn babies who required antibiotics for the MT-RNR1 genetic variant. Nurses conducted a cheek swab in the babies which was then inserted into a bedside machine for analysis.

The researchers also compared the mean times in giving the proper antibiotic to the babies screened with and without the new genetic test. They found that the mean times were almost the same, taking about 55 minutes. This means that including the new genetic test in clinical practice does not negatively impact the delivery of care.

To the researchers' knowledge, there are no genetic tests that could screen for the genetic variant in question within the critical first hour when antibiotics should be given to babies with severe infections. This is faster than previous genetic tests which normally would have taken several days.

The genetic test has already benefited some families as conveyed by first year nursing student Mary about her baby Khobi: 'Khobi was born with her bowel outside her tummy, which put her at risk of infection she needed antibiotics quickly but was given this new genetic test which showed she was susceptible to hearing loss from gentamicin... She was given an alternative antibiotic which didn't affect her hearing'.

Over 300 nurses are now being trained to use the machines across hospitals in Manchester, and it is expected the use of the test will become routine for babies who need antibiotic treatment in hospitalswithin weeks.

However, the new Genedrive MT-RNR1 genetic test should not be confused with gene drive a way of using genome editing to replace a natural gene with a new gene, that then gets passed on from generation to generation. Such gene drive technology only works on animals with short reproduction cycles, such as mosquitoes.

Follow this link:
Rapid genetic test to identify babies at risk of antibiotic-induced hearing loss - BioNews

Recommendation and review posted by Bethany Smith

PHILADELPHIA -- Robert H. Vonderheide, MD, DPhil, has been appointed to a second five-year term as director of the Abramson Cancer Center (ACC) at the University of Pennsylvania, following a highly successful tenure that saw 17 FDA approvals in oncology for therapies based on studies led or co-led by ACC investigators, high-impact basic and translational research discoveries, expansion of radiation oncology services to new sites across the Philadelphia region, and development of new methods for live tumor imaging during surgeries. Under his leadership, the ACC has also launched new cancer home care and telemedicine programs, and initiatives that drove improvements in germline genetic testing, cancer screenings and clinical trial participation by minority patients. He will continue in his roles as Vice President for Cancer Programs for the University of Pennsylvania Health System and Vice Dean for Cancer Programs in Penns Perelman School of Medicine.

In the next phase of his leadership, Dr. Vonderheide will build on the development of pathways to ensure that amid the increasingly complex landscape of cancer care and research patients across the entire health system are able to access leading-edge Penn Medicine care no matter where they live. Among key examples already underway: Proton therapy at Lancaster General Health and Virtua Health in New Jersey, both set to open this year; sub-specialty surgery consultation at outpatient sites and Penn Medicines regional hospitals; and telemedical options for genetic counseling and CAR T cell therapy and bone marrow transplant evaluation and education.

Patients can expect an exceptional experience at every location across our health system a place they are cared for by the most committed staff, specialized nurses, and top physician experts. Now, we are harmonizing that patient experience to ensure that every patient has the most seamless care and robust options across different sites of care, and the assistance to navigate easily between them, said University of Pennsylvania Health System CEO Kevin B. Mahoney. Under Dr. Vonderheides leadership, we are ensuring that every patient has every opportunity for the most personalized treatment and the very best chance at a cure through every door they enter across Penn Medicine.

Vonderheides renewal as ACC director includes a five-year, $130 million investment from the health system to provide resources and infrastructure to unify all missions of cancer care and research across Penn Medicine.

Growing access to cancer clinical trials is a key area of focus, through the development of a cancer clinical trials network, including more opportunities for patients at Penn Medicines regional hospitals to participate in clinical trials being led at the ACCs main campus sites in Philadelphia, and the expansion of other trial sites closer to patients homes. Additional efforts will harness the power of Penns unified electronic health record, from new approaches to involve patients in the Penn Medicine BioBank to expansion of programs providing patients with e-nudges to schedule mammograms and other tests and appointments through the MyPennMedicine portal.

This is a time of exciting, unprecedented momentum for cancer care and research. The cancer death rate has dropped faster in the past two years than ever before, due in part to the development of prevention strategies and of targeted and immunotherapies for an array of diseases, said J. Larry Jameson, MD, PhD, dean of the Perelman School of Medicine and Executive Vice President of the University of Pennsylvania for the Health System. Dr. Vonderheide embodies that momentum, as an exceptional collaborator who brings experts together across different disciplines to focus efforts on the most innovative ways to meet our shared goals of driving cancer discovery and improving patient care.

The ACC has continuously been designated as a Comprehensive Cancer Center by the National Cancer Institute (NCI) since 1973, one of 52 such Centers in the United States. It is among the nations most highly ranked cancer centers, providing care to adults during more than 300,000 outpatient visits annually across the six-hospital Penn Medicine Cancer System, as well as delivering more than 190,000 outpatient infusion therapies, over 130,000 radiation treatments and 330 stem cell transplants each year. The ACC was rated as exceptional during its competitive research funding review, the highest possible merit rating for an NCI Cancer Center.

Dr. Vonderheide is a leading authority in cancer immunology, leading a lab and clinical research focused on immunotherapies and vaccines for pancreatic, breast, and other cancers. He serves on the boards of directors for the American Association of Cancer Research, the American Association of Cancer Institutes, and the National Comprehensive Cancer Network. He is a member of the NCI Board of Scientific Advisers.

He received his bachelors degree in chemical engineering from the University of Notre Dame, and is a graduate of the Harvard Medical School, as well as Oxford University, where he earned a doctorate in immunology as a Rhodes Scholar. He completed residency training in internal medicine at Massachusetts General Hospital and a fellowship in medical oncology at the Dana Farber Cancer Institute.

Penn Medicineis one of the worlds leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of theRaymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nations first medical school) and theUniversity of Pennsylvania Health System, which together form a $9.9 billion enterprise.

The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according toU.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $546 million awarded in the 2021 fiscal year.

The University of Pennsylvania Health Systems patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Centerwhich are recognized as one of the nations top Honor Roll hospitals byU.S. News & World ReportChester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nations first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.

Penn Medicine is powered by a talented and dedicated workforce of more than 52,000 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2021, Penn Medicine provided more than $619 million to benefit our community.

Read more:
Penn Medicine Appoints Robert Vonderheide to Second Five-Year Term as Director of the Abramson Cancer Center - Penn Medicine

Recommendation and review posted by Bethany Smith

In 2014, Barbara Small was a pediatric nurse at Childrens Hospital of Philadelphia, enjoying her work, her family, and traveling with her husband, Dave. She was an active 55-year-old until she broke her hip in a bike accident.

A week after surgery to repair her hip, her vision became blurry. She went to the walk-in clinic at Penn Presbyterians Scheie Eye Institute and learned that her optic nerve was damaged, but that it didnt have anything to do with her accident or surgery.

Soon after, she awoke one morning and couldnt control her left side. The emergency room doctor told her shed had a stroke and sent her to a neurologist. An MRI revealed she had a brain lesion, apparently an area of tissue that had been damaged by the stroke.

Over the next few years, as her eyesight continued to deteriorate, repeated MRIs showed more brain lesions. Small visited a low-vision specialist, retinologist, endocrinologist, hematologist, rheumatologist and three cardiologists. She was tested for multiple sclerosis, diabetes, and a host of other diseases. She didnt have any of them.

I didnt think they would ever find anything, that the tests would all be negative, recalled Small, now 63. I wasnt optimistic about getting a diagnosis but I felt like I could overcome and manage whatever was wrong.

Doctors did diagnose a number of issues, including retinopathy, a disease of the retina that can impair vision, and neovascularization, the growth of blood vessels that are part of abnormal tissue, such as tumors, and of course, those lesions on her brain. She was also seeing a physical therapist for balance issues. But what connected these diagnoses remained elusive.

Small often thought about her mother, who died while in her 40s of an illness that was never diagnosed. When Small graduated from nursing school, she looked at her mothers medical records, which showed hardening of the arteries, arterial sclerosis, collagen disease, cardiac arrhythmias, and liver and kidney failure.

They summarized it as multisystem failures, Small said.

Her mother, who died in 1969, hadnt displayed any brain or eye symptoms, however. And her father, who lived into his late 80s, never spoke about his wifes illness.

In January 2018, almost four years after Smalls first symptoms, her neurologist sent her for genetic testing.

When I saw the geneticist, I said, This will be my last doctor, Small said. The geneticist tested me for four different genetic diseases that involve the brain and the eye and I tested positive for the TREX 1 gene mutation.

Small was diagnosed with RVCL retinal vasculopathy with cerebral leukoencephalopathy an extremely rare, inherited disease with no known cure.

Patients with RVCL are typically healthy until the fourth or fifth decades of life, and then they suddenly start to develop a variety of symptoms that can affect multiple organs, but especially the brain and the eye, said Jonathan Miner, associate professor of medicine and director of the RVCL Research Center at Penn Medicine.

Its a relentless disease that results in premature death in 100% of cases, in many cases within five or 10 years of onset.

As devastating as the news was, Small also had some measure of relief to be able to put a name to her constellation of issues.

I thought they would never find anything, that I would just have these odd symptoms, she recalled. Luckily, I had good doctors at Penn who did the research and were on this journey with me, trying to figure it out. They gave me a lot of resources so I felt very well-informed.

Uncovering Smalls diagnosis was difficult because RVCL is so rare just 43 families in the world are known to have it.

I suspect there are many more RVCL patients who just havent been diagnosed yet, Miner said. The disease can be confused with other diseases, like multiple sclerosis, lupus or brain tumors.

Disease of the retina is a hallmark of RVCL, but it can look very similar to diabetic eye disease.

The patients will end up losing vision, can develop glaucoma or blood vessel disease in the retina, dementia, cognitive impairment, memory problems, difficulty speaking or walking, and stroke symptoms, he said. A lot of patients have kidney, liver or thyroid disease. In all cases, without having a genetic test, these findings can end up being attributed to something else.

Within families with the disease, 50% will inherit the mutation that causes RVCL, and 100% of those with the mutation will develop the disease, Miner said. Since her diagnosis, Smalls family has undergone genetic testing that has uncovered more cases, including in one of her daughters and her brother. Small suspects that her mother had it, too, though her symptoms were different from her own.

Smalls brother, James Davis, 67, discovered that he had RVCL in July 2021. He had been getting injections in his right eye to treat vision problems for several years and later developed glaucoma. Otherwise, he felt fine until he didnt.

In June of 2021, I had extreme fatigue, loss of appetite, problems with my right eye, and funky walking, said Davis, who lives in Plymouth, Minn.

An MRI showed lesions concerning for possible malignancy, so he was expecting he might need treatment for brain cancer. When he shared the news with his sister, she put him in touch with Miner, who asked Davis to hold off on seeking additional evaluation until he had genetic testing. The test confirmed that Davis, too, had the TREX 1 gene mutation.

It was a big shock, said Davis. We talked to our financial planner to be sure theres sufficient money for my wife, Dale, and were trying to enjoy things as much as we can because my life expectancy is a lot shorter than we planned.

Davis son is 27 and plans to have genetic counseling and testing soon.

Shortly after Smalls diagnosis, her daughters Kimberly Antonelli, 35, and Lindsay Ward, 32, had genetic counseling, and were told that many people dont want to be tested because they fear the results and think that they cant do anything about them. They saw it differently.

Getting tested was a very easy decision for me, said Ward, who lives in West Deptford. Knowledge is power. But it was a very hard eight weeks waiting for the results.

She was especially anxious for her son, Declan, now 4. She does have the mutation, which means Declan might, as well.

I had prepared myself for the worst, she recalled. In a weird way I felt it was a positive for my mom because now were in this together. I always try to see the bright side of things but obviously I was devastated. To think my future might not be as long as I had anticipated was hard.

Hoping to become pregnant again, Ward went through preimplantation genetic diagnosis (PGD,) a laboratory procedure used in conjunction with in vitro fertilization (IVF) to reduce the risk of passing on inherited conditions.

We had seven embryos. Four had the mutation and three did not, she recalled. I did three rounds of IVF and all resulted in eventual miscarriage. It had taken such an emotional, physical and mental toll on me that I couldnt do it again. We had our son, Jason, who is now 8 months old, naturally.

Ward hopes that by the time her children grow up, there will be treatments or even a cure for RVCL, should they turn out to have the mutation. She has decided to wait on testing them so that they can make the choice together when they are older.

I take things more seriously and live more for the moment because at any point I could have the onset or my moms could get worse, she said. This morning we went to get a dozen specialty doughnuts, and, why not! Youve got to live life.

Her big sister, Kimberly, was relieved to find out that she doesnt have the gene, and so neither do her four children. Yet her joy for them is tempered by grief. Im happy that Im negative but Im sad that my other family members arent, said Antonelli, who lives near Pittsburgh. My sister and I are very close.

Another source of stress is the fact that few people can really understand what its like to have such a rare condition.

You can sympathize with people who have cancer because you understand it, Antonelli said. My mom has a death sentence but people cant appreciate how dangerous and unknown these rare diseases are. There are very few visible symptoms.

Miner, who came to Philadelphia from St. Louis in 2021 to lead Penn Medicines research center, is among numerous experts seeking answers to RVCL.

What motivates me is knowing that this is a solvable problem because its a disease caused by a single gene mutation, he said. This disease is going to be eventually treatable and hopefully cured, but we dont know how long its going to take, five years or 15 years.

Unlike many other diseases, RVCL is due to one protein encoded by one gene, said Miner. Now that we know the genetic cause, were hoping to be able to develop personalized medicines for these patients and their families. Understanding this particular gene and protein is about far, far more than this specific disease. The drugs that are being developed to target the TREX 1 protein are very likely to become useful for other diseases, as well.

Small has some weakness on her left side, which causes a slight limp; her vision is impaired; and she tires easily. She left her nursing job in October 2019.

Now that her husband, Dave, is retired, they are enjoying travel and spending time with their family. She maintains an optimistic outlook, hopeful that progress will be made in unlocking the mysteries of RVCL, if not for her then for her children, grandchildren and future generations.

My outlook is good, she said. My husband tells me Im going to live until Im 80. Im not going to live until Im 80 but thats OK. Im much more likely not to make it out of my 60s but that doesnt depress me. Its just the way its working out.

Read more from the original source:
Medical mystery: This woman's brain lesions led to a diagnosis that affected her entire family - The Philadelphia Inquirer

Recommendation and review posted by Bethany Smith

New York, United States The Predictive Genetic Testing And Consumer Genomics Market research report provides all the information related to the industry. It gives the outlook of the market by giving authentic data to its client which helps to make essential decisions. It gives an overview of the market which includes its definition, applications and developments and manufacturing technology. This Predictive Genetic Testing And Consumer Genomics market research report tracks all the recent developments and innovations in the market. It gives the data regarding the obstacles while establishing the business and guides to overcome the upcoming challenges and obstacles.

Get the PDF Sample Copy (Including FULL TOC, Graphs and Tables) of this report @:

https://www.a2zmarketresearch.com/sample-request/571656

Competitive landscape:

This Predictive Genetic Testing And Consumer Genomics research report throws light on the major market players thriving in the market; it tracks their business strategies, financial status and upcoming products.

Some of the Top companies Influencing in this Market include:23andMe, Inc., Myriad Genetics, Inc., F.Hoffmann-La Roche Ltd., Abbott Laboratories, Genesis Genetics, Agilent Technologies, Thermo Fisher Scientific, Inc., BGI, Bio-Rad Laboratories Inc., Illumina, Inc., Counsyl, Inc., ARUP Laboratories

Market Scenario:

Firstly, this Predictive Genetic Testing And Consumer Genomics research report introduces the market by providing the overview which includes definition, applications, product launches, developments, challenges and regions. The market is forecasted to reveal strong development by driven consumption in various markets. An analysis of the current market designs and other basic characteristic is provided in thePredictive Genetic Testing And Consumer Genomics report.

Global Predictive Genetic Testing And Consumer Genomics Market Segmentation:

Market Segmentation: By Type

Genetic Susceptibility TestNutria GeneticsSkin & Metabolism GeneticsOthers

Market Segmentation: By Application

Breast & Ovarian CancerCardiovascular screeningDiabetic Screening & MonitoringOthers

Regional Coverage:

The region wise coverage of the market is mentioned in the report, mainly focusing on the regions:

Get Up to 30% Discount on the first purchase of this report @:

https://www.a2zmarketresearch.com/discount/571656

An assessment of the market attractiveness with regard to the competition that new players and products are likely to present to older ones has been provided in the publication. The research report also mentions the innovations, new developments, marketing strategies, branding techniques, and products of the key participants present in the global Predictive Genetic Testing And Consumer Genomics market. To present a clear vision of the market the competitive landscape has been thoroughly analyzed utilizing the value chain analysis. The opportunities and threats present in the future for the key market players have also been emphasized in the publication.

This report aims to provide:

Table of Contents

Global Predictive Genetic Testing And Consumer Genomics Market Research Report 2022 2029

Chapter 1 Predictive Genetic Testing And Consumer Genomics Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Predictive Genetic Testing And Consumer Genomics Market Forecast

Buy Exclusive Report @: https://www.a2zmarketresearch.com/checkout

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

sales@a2zmarketresearch.com

+1 775 237 4147

View original post here:
Predictive Genetic Testing And Consumer Genomics Market Report Covers Future Trends With Research 2022 to 2029 23andMe, Inc., Myriad Genetics ...

Recommendation and review posted by Bethany Smith

Breast pain can be worrisome, but its not usually a cause for concern.

Hormones play a big role in the development of breast tissue and the pain that can develop there. This is especially true in women, as hormone fluctuations cause ducts and glands in the breasts to grow and shrink in cycles.

This article will explore the causes of breast pain, as well as when to contact a doctor and how theyll diagnose your symptoms.

While anyone can experience breast pain, its more common in people with female sex hormones like estrogen and progesterone. These hormones play a big role in the fluctuation of breast tissue structure and size.

During significant hormonal shifts like pregnancy and while breastfeeding, breast pain or tenderness is actually expected.

Most types of breast pain fit into two categories: cyclic and noncyclic breast pain.

Cyclic breast pain is linked to your menstrual cycle and is believed to be caused in part by hormone changes. Pain can develop at different points in this cycle. But its most common at the start of the cycle or during ovulation.

Cyclic breast pain is barely noticeable for some people and excruciating for others. Its not uncommon for this pain to be felt in just one breast or the other. It is often a radiating pain that begins near the armpit.

Noncyclic breast pain can occur at any time and is not linked to your menstrual cycle. This type of pain is pretty uncommon. It can be caused by all kinds of things, like trauma, an injury to the breast tissue, or even arthritic pain. The type of pain can vary, but its usually a continuous pain that is felt in one specific area of the breast. It can be sharp, dull, or radiating.

Cyclic and noncyclic causes of breast pain include things like:

Most causes of breast pain will go away on their own with time, medications, or lifestyle changes. However, if youre experiencing any of the following symptoms, schedule an appointment with a doctor for an evaluation and diagnosis:

Your doctor will begin an examination for breast pain by asking you about your personal and family medical history. Theyll want to know which of your relatives if any have had breast cancer and at what age.

Genetic testing using your blood or saliva could provide clues about your cancer risk. But there are other considerations in your family history, too.

Your doctor may suggest a one-time or regular mammogram to examine your breast tissue more closely. The U.S. Preventive Services Task Force recommends that all women between the ages of 50 and 74 receive a mammogram at least once every 2 years. Get one more often if you have an increased risk of breast cancer.

Other tools that can help identify tissue changes, breast cancer, or other conditions may include:

Biopsies are the tool of choice when it comes to diagnosing breast lumps, which are often associated with a higher risk of cancer.

A mammogram is usually the go-to tool when it comes to diagnosing breast pain and other issues, but ultrasound imaging is sometimes more accurate in people under 30 years old. Mammograms are highly accurate at detecting cancer, though, especially in older adults.

Treatment of your breast pain depends on the cause. Breast cancer treatment is complex and depends on the cancer type and stage.

Most breast pain, however, can be addressed with medications or lifestyle changes. Some things that you can do to relieve breast pain:

Breast pain is common and usually not serious. Most women will experience breast pain at some point in their lives, but only a few will be diagnosed with a serious problem like cancer.

If you have concerns about your breast pain, talk with a doctor about your symptoms. Be sure to follow their recommendations for regular screenings.

Discussing your risk factors including family and genetic history can help you and your doctor make the best decisions regarding your breast health.

Excerpt from:
When to Worry About Breast Pain: Causes, Diagnosis, Treatment - Healthline

Recommendation and review posted by Bethany Smith

Did you know that your babys genetic makeup was determined at conception? From the moment the sperm met the egg, your little ones genetic code DNA began forming. Its made up of 23 pairs of chromosomes. Sometimes, though, extra chromosomes make their way into the mix and can result in something called a trisomy.

Edwards syndrome is also known as trisomy 18. It means a person has an extra copy of chromosome number 18, leading to issues with development. Heres more about the symptoms of this syndrome, what causes it, and what you might expect after a diagnosis.

Trisomy 18 is a rare genetic disorder that affects approximately 1 in every 3,315 births in the United States around 1,187 babies each year.

In typical development, a baby gets 23 pairs of chromosomes from its parents during conception 22 are called autosomes, and 1 set is made up of sex chromosomes (X and/or Y, depending on the babys sex).

The word trisomy means three bodies. When there are three copies of the chromosome versus the usual two, it creates an imbalance. As a result, a baby may be born with certain structural changes some of which may lead to miscarriage, stillbirth, or death after the baby is born.

Babies can be born with an extra copy of chromosome 18 in each cell in the body. This is called complete trisomy 18 and causes more serious health outcomes.

Mosaic trisomy 18 happens when only some cells in the body contain the extra chromosome. Around 5 percent of babies with trisomy 18 have the mosaic form. This generally leads to milder irregularities and longer life expectancy.

Partial trisomy 18 happens when an extra copy of chromosome 18 attaches to another chromosome. Again, the severity of the syndrome tends to be associated with the total number of cells affected by the trisomy. So, a partial trisomy tends to have less severe effects and longer life expectancy.

You may not notice anything different in your pregnancy if your baby has Edwards syndrome. In fact, you may not learn about your babys diagnosis until after your doctor orders certain prenatal screening tests, like:

Some families do not discover their childs diagnosis until birth, when the following physical features may include:

Other health issues may include:

Trisomy 18 is caused by any situation that leads to an extra copy of chromosome 18 in the body.

In most cases, it happens when the sperm meets the egg during conception. In one scenario, the reproductive material of either parent may spontaneously divide. In another, the trisomy may happen as cells divide after fertilization. Whatever the case, the extra chromosome happens at random.

Translocation is another possibility, which means that parts of chromosomes break off and attach to other chromosomes. This may happen randomly or through a balanced translocation, in which one parent has a set of chromosomes that arent typical but are balanced. When chromosomes are balanced, they dont cause medical issues. After reproduction, though, genetic information passed on may cause a trisomy.

Edwards syndrome may be diagnosed at some point during your pregnancy. You may have a cell-free DNA screening (cfDNA) at any time after 10 weeks of pregnancy and until delivery. cfDNA is a simple blood test that screens for genetic conditions. A positive result on this test means youll need further testing to confirm the results.

Other tests during pregnancy include:

Other times, trisomy 18 may not be diagnosed until after your baby is born. Your childs doctor may diagnose it based on:

There is no cure for trisomy 18. Since babies with this condition tend to have multiple health issues, youll work with a team of doctors to create a customized treatment plan. In more severe cases, some families favor palliative care or hospice care.

Treatments are more about making a child comfortable or correcting the issues that affect an individual child. For example, surgery may be an option to treat things like:

As a child grows, they may need support academically and physically. Early intervention and special education programs can help fill these gaps.

You may be surprised to learn that there are very few risk factors for Edwards syndrome.

There may be an increased chance of having a baby with a trisomy as you get older. While different reports show mothers in their late teens and 20s can have children with trisomy 18, the mean age is closer to 32.5 years old.

In rare cases, trisomy 18 may be inherited from a biological parent (through balanced translocation). If you already have had one child with a trisomy, your doctor may suggest getting genetic testing to assess your chances of having another child with a similar condition.

The vast majority of the time, though, Edwards syndrome happens by chance during conception when the sperm meets the egg.

Its important to be prepared for all possibilities with a condition like trisomy 18. Researchers share that nearly half of all babies born with Edwards syndrome who survive delivery may not live beyond the first week of life.

That said, the severity of the syndrome depends on the type (complete, mosaic, partial, etc.) and whatever effects it has on your individual child. All children are different, and all outlooks will be unique as a result.

Of children born with Edwards syndrome, nearly 50 percent will not survive beyond the first week of life. However, around 10 percent will reach their first birthday, and some may live to their teen years or even adulthood, but they will need medical support or therapies, including:

While you may be worried about your child and the outlook over the long term, try taking it day by day. And dont forget about yourself or your own mental health in the process.

There is support for families with children who have Edwards syndrome. Consider contacting the Trisomy 18 Foundation or the Support Organization for Trisomy 13, 18, and Related Disorders (SOFT). Your doctor may also be able to help connect you with a local group for support and other resources.

View original post here:
Trisomy 18: Diagnosis, Causes, Prognosis, and More - Healthline

Recommendation and review posted by Bethany Smith

After that, you sit back and you wait for your results to come in and you wait for information to come to you. So if there's a new survey that comes out, well let you know, and it's up to the individual, how much, or how little they want to participate. Again, we'd love everyone to continue to complete the surveys as they go along because the more information that we have about lifestyle, environment, family health history, social determinants of health, all of that helps researchers have a more dynamic and full understanding of what is going on. Not only with the individual, but they can see it on a larger scale in communities and different populations.

La Keisha Jones:One thing with a trial is that you are providing treatment. We do not provide treatment. We are just collecting information to create a data cohort of information for researchers to look at and that would be the difference there. The one thing that we do offer, though, is that if something is discovered individuals are notified. If there is something of health significance with the genetic results that is found, then a genetic counselor is offered to them to explain what this means to them and what it can mean to their family.

Our program is giving information back so that people can have more informed conversations. They can be more informed about their risk for a disease possibly, or the risks that they may or may not face. Again, if something comes back, it doesn't necessarily mean that disease could take place, but if they are aware of it, they can keep it to themselves or they could share it with their family, or they could take it to their doctor and just say, "Hey, you know, we would never have known this because genetic testing isn't on the list of things that normally take place and I might be at risk. What should we do about it?" Maybe it means earlier screenings. Maybe it means making healthier decisions.

There are also different levels of participation. Some people just decide they want to do the online portion. Some people want to provide genetic information but not to receive their results. You have the option to say yes, no, maybe, or I don't know yet.

Lakeisha Jones:Anyone over the age of 18 can enroll. It doesn't matter if you have any diseases or don't have any diseases, anything of that sort. We do ask individuals to have an address in the U.S. and contact information here in the U.S. for about six months out of the year, just so that when information is returned, they can make sure that they can be followed up with and be contacted. You don't need health insurance to participate and you do not need to be a U.S. citizen.

That's the beautiful thing about New York, too, we have a very diverse staff. Our staff is bilingual, English and Spanish.

To sign up online or find phone numbers of where to talk to someone about the program, you can visit the New York City Consortium websiteor call 212-205-9927.

Here is the original post:
The 'All of Us' Research Program Is Helping Make Medicine More Precise for Diverse Populations. Five Years In, How Is It Going? - Columbia | Neighbors

Recommendation and review posted by Bethany Smith

Familial cancer syndrome is a genetic condition that increases the risk of various cancers in related family members. Hereditary cancer disorders are caused by mutations in certain genes passed down from parents to offspring, and certain cancer patterns can be found in families with hereditary cancer syndrome.

This could be due to other causes like the fact that family members share certain activities or exposures that raise cancer risk, such as smoking. Rarely, factors that run in families, such as obesity, may also increase cancer risk.

The common cancers and associated syndromes:

Hereditary Breast and Ovarian Cancer (HBOC) syndrome: tumors are commonly found in women younger than the average age and are caused by a hereditary mutation in either the BRCA1 or BRCA2 gene.

Lynch syndrome: also known as hereditary non-polyposis colorectal cancer, is the most common genetic syndrome that raises a person's risk of colon cancer in those under the age of 50.

Li-Fraumeni syndrome: a rare genetic disease that causes a variety of malignancies in individuals in their twenties and thirties, including sarcoma, leukemia, brain tumors, adrenal cortex cancer, and breast cancer.

Genetic counseling and testing: People with a strong family history of cancer may be interested in learning more about their genetic composition. Since hereditary mutations impact all cells in a person's body, genetic testing on blood or saliva samples is frequently used to detect them.

Germline mutation

Any observable alteration within germ cells is referred to as a germline/germinal mutation. When a mutant sperm or oocyte combine to form a zygote, the only mutations that can be passed on to progeny are those in these cells.

Individuals with mutations in tumor suppressor genes or proto-oncogenes are more likely to develop tumors. About 5-10% of all cancers are inherited through defective inherited genetic alterations.

Because the protein produced inhibits tumors, those who inherit germline mutations in TP53 are prone to specific cancer types. Breast and ovarian cancer as well as hereditary non-polyposis colorectal cancer, are two further examples.

Indias stance on family cancer syndrome

According to the WHO and the American Cancer Society, cancer kills one out of every six people on the planet, more than HIV/AIDS, TB, and malaria combined.

Are these genetic tests available in India?

Yes, these genetic tests are now accessible in India and require only a simple blood test (Multi-gene panel testing).

Who must undergo these tests?

Strong family history of Cancers like Breast cancer, Ovarian cancer, Colon cancer etc. happening in multiple family members and or many generations needs to get tested.

When cancer happens at an early age say <30 years, needs to be tested again.

There are other situations where one needs to get tested for which they can consult their Oncologist or physician.

What preventive strategies are available?

Those who test positive for these syndromes have a few cancer prevention options like preventive surgeries, tablets, and also aggressive cancer screening programs to detect cancers at early stages and treat them effectively.

This data can help clinicians make better clinical management decisions. Furthermore, mutations in particular genes boost therapeutic response, contributing to precision/personalized medicine, in which patients are treated depending on their mutations.

Given the numerous benefits of detecting genetic differences in hereditary malignancies, the medical community has been working to make genetic testing more affordable and accessible to the general people, allowing for faster disease diagnosis, management, and treatment.

-The author Dr. Vivek Belathur is MD, DM, ECMO, Senior Consultant Medical Oncology at Fortis Hospitals, Bannerghatta Road. The views expressed are personal.

(Edited by : Priyanka Deshpande)

First Published:Apr 07, 2022, 08:42 PM IST

Read the original:
World Health Day | Family Cancer Syndrome: What genes tell us about the risk of developing cancer - CNBCTV18

Recommendation and review posted by Bethany Smith

DEDUCE study demonstrates AUC of 0.86 in overall cohort, including more than 700 prospective samples

AUSTIN, Texas, April 13, 2022 /PRNewswire/ --Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, todayannounced that its clinical validation study1 on its donor-derived cell-free DNA (dd-cfDNA) test for the assessment of acute rejection in heart transplant patients, Prospera Heart, has been published in the Journal of Heart and Lung Transplantation - a leading journal with the highest impact factor in the transplantation sector2.

This multi-site clinical validation, named the DEDUCE study, was conducted in partnership with the University of Utah and the University of California, San Diego and evaluated 703 prospective and 108 retrospective samples, (811 samples total) from 223 patients. The patient cohort included a large number of biopsy-confirmed rejections - 32 samples correlating to antibody mediated rejection (AMR) and 17 samples correlating to acute cellular rejection (ACR). The Prospera Heart test exhibited excellent performance with an overall 0.86 AUC for identifying acute rejection. Notably, the performance was also exceptional in the prospective arm-alone (0.87 AUC3).

"There is a critical unmet need for an accurate and less invasive approach for rejection surveillance after heart transplant," said Josef Stehlik, senior author and medical director of the Heart Transplant Program and co-chief of the Advanced Heart Failure Program at the University of Utah School of Medicine. "Incorporation of a noninvasive assay to reduce or replace the use of endomyocardial biopsy requires a very high performance standard. The Prospera Heart test demonstrated performance that I believe the clinicians will be very excited about."

The study also included an analysis on the use of dd-cfDNA concentration alone to identify rejection. dd-cfDNA concentration demonstrated an AUC of 0.88 overall, and 0.89 in the prospective cohort, highlighting the potential (upon additional studies and evaluation) to further improve the performance of the Prospera Heart test by evaluating both dd-cfDNA concentration and donor fraction.

The Prospera Heart test was launched in late 2021 and will continue to be evaluated in a variety of additional studies, including the NIH-supported DTRT study, and the Natera-sponsored DETECT trial, expected to be the first randomized controlled trial comparing dd-cfDNA surveillance to endomyocardial biopsy surveillance in patients of all risk profiles from 30 days post transplant. Combined, these trials are expected to include more than 775 heart transplant patients across multiple centers, underscoring Natera's commitment to generating robust scientific evidence.

About the Prospera test

TheProsperatest leverages Natera's core single-nucleotide (SNP)-based massively multiplexed PCR (mmPCR) technology to identify allograft rejection non-invasively and with high precision and accuracy, without the need for prior donor or recipient genotyping. The test works by measuring the fraction of donor-derived cell-free DNA (dd-cfDNA) in the recipient's blood. It may be used by physicians considering the diagnosis of active rejection, helping to rule in or out this condition when evaluating the need for diagnostic testing or the results of an invasive biopsy. The Prospera test has been clinically and analytically validated for performance regardless of donor relatedness, rejection type, and clinical presentation. It has been developed and its performance characteristics determined by Natera, the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified.

About Natera

Natera is a global leader in cell-free DNA testing, dedicated to oncology, women's health, and organ health. Our aim is to make personalized genetic testing and diagnostics part of the standard of care to protect health and enable earlier and more targeted interventions that help lead to longer, healthier lives. Natera's tests are validated by more than 100 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit http://www.natera.com.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, whether the results of clinical or other studies will support the use of our product offerings, our expectations of the reliability, accuracy and performance of our screening tests, or of the benefits of our screening tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available atwww.natera.com/investorsandwww.sec.gov.

ContactsInvestor Relations:Mike Brophy, CFO, Natera, Inc., 510-826-2350Media:Kate Stabrawa, Communications, Natera, Inc., 720-318-4080[emailprotected]

References

SOURCE Natera, Inc.

Excerpt from:
Multi-Site Clinical Validation of Prospera Heart Test Demonstrates Outstanding Performance in Assessing Heart Transplant Rejection - PR Newswire

Recommendation and review posted by Bethany Smith

Image: Professor John Yarnold (left), Professor Pascal Meier (middle) and Professor Clare Isacke.Credit:soora.co.uk

As research efforts become bigger and more ambitious, there is a real need to bring together researchers with diverse scientific backgrounds and perspectives to solve complex scientific problems. This type of multidisciplinary approach taken by The Breast Cancer Team at the ICR and The Royal Marsden NHS Foundation Trusthas been critical to their success in making transformational discoveries in breast cancer.

Twelve researchers from the ICR and The Royal Marsden Breast Cancer Team have been awarded the 2022 Team Science Award from the American Association for Cancer Research (AACR). The award recognises the significant contributions to the breast cancer research community made by the multidisciplinary team spanning a spectrum of discovery biology, molecular pathology, trial statistics and clinical science.

Here, we celebrate the teams tremendous achievements, which are underpinned by more than two decades of research.

In 1995, Professor Alan Ashworth, then at the ICR but now President of the UCSF Helen Diller Family Comprehensive Cancer Center, was part of a team of researchers that discovered the second breast cancer susceptibility gene, BRCA2. Building on this work, Professor Ashworth and Professor Andrew Tutt(then Ashworths MRC Clinical Training Fellow and PhD student), along with a wider group in the Ashworth lab, uncovered the important role of the BRCA2 gene in DNA damage repair revealing how it might be targeted with drugs such as carboplatin.

Together with Professor Chris Lordwho had joined the lab, and Professor Steve Jacksonsteam at the UK biotech company KuDOS, in 2005, they went on to identify the first synthetic lethal interaction between the BRCA1/2 genes and the DNA damage repairing enzyme Poly-ADP-Ribose Polymerase 1, or PARP1.

The concept of synthetic lethality is based on the dependency between a pair of cancer genes, where loss of function of either individual gene will allow the cancer cell to survive, but loss of function of both genes simultaneously will cause the cancer cell to die.

The collaboration with the KuDOS team, who had discovered a PARP inhibitor drug called olaparib, showed that blocking PARP1 caused cancer cells carrying BRCA1 or BRCA2 mutations to die. The striking results from the Ashworth lab stimulated Professor Tutt and the Ashworth group to design a Phase I clinical trial in 2008, together with ICR clinician scientist Professor Johann de Bonoand Professor Stan Kayeat The Royal Marsden, that focussed on BRCA1/2 mutation carriers.

Commenting on the discoveries, Professor Lord said, I think we knew from a very early stage that this was quite a significant finding. But at the time, we didnt fully realise that it would go all the way to actually getting approved and used worldwide. For us lab scientists and clinician scientists, these are things that we came into research to do. From an emotional perspective, it is incredibly rewarding and an enormous privilege to be able to contribute to things that actually make a difference to people.

The teams collaborative efforts pioneered the use of synthetic lethality as a new therapeutic strategy in cancer. This has had a particular impact in breast cancer, as well as in ovarian, prostate and pancreatic cancer, where PARP inhibitors are also now used.

Phase III trials with olaparib, that followed the phase II proof of concept studies led by Professor Tutt in 2010, resulted in the drugs approval in treating advanced BRCA1/2 mutated breast cancers. Olaparib was approved for breast cancer by regulators in the US, the Food and Drug Administration (FDA), in 2018, and in Europe, the European Medicines Agency (EMA), in 2019. The FDA and EMA have also approved the use of olaparib in ovarian, prostate and pancreatic cancers.

The development and approval of olaparib has transformed how advanced BRCA1/2 mutated breast cancers are treated worldwide. Olaparib is the first cancer treatment targeted against an inherited genetic fault. This breakthrough has had a huge impact on thousands of people with breast cancer, enabling patients to live longer and have a better quality of life while receiving treatment.

More recently, the results from the OlympiA trial, that was led by Professor Tutt as the Breast International Groups Global OlympiA Steering Committee Chair,revealed that adding olaparib to standard treatment for early-stage breast cancer in patients with inherited BRCA1/2 mutations can improve survival and reduce the risk of recurrence. The trial also supports testing for germline BRCA1/2 mutations, which has now been established as an important part of treatment selection in early breast cancer. The teams findings have impacted international treatment guidelines for both breast cancer therapy and genetic testing.

Professor Tutt said, This work brought together fundamental biologists, geneticists, biotech companies, early phase trials leaders and international collaborators at the phase III study stage. The award recognises the teamwork and amalgamation of skillsets required to change the way breast cancer is treated.

While the use of PARP inhibitors has been largely successful, not all patients who have inherited a faulty BRCA1 or BRCA2 gene respond to PARP inhibitors. Professors Lord and Tutt and their team are trying to understand how cancer cells become resistant to these drugs. They are uncovering ways to overcome resistance by identifying molecules that can be targeted using different drug combinations.

Developing smarter, kinder treatments for patients is a continuous cycle from the lab to the clinic and back again. Professor Lord said, Our collaboration with The Royal Marsden allows us to be a truly translational research centre. We can do biological research that informs new drug discovery projects and design of clinical trials, but we can also take observations from the clinic and feed them back into the lab where they can be dissected at a molecular level. This provides useful insight that can help to make new discoveries to overcome drug resistance.

Our researchers regularly present their latest findings at the AACR Annual Meeting in the US.

Find our more about the AACR conference

Oestrogen receptor positive, or ER+, breast cancer is the most common form of the disease it makes up about 80 per cent of cases and this is where the joint team made another major contribution recognised by the award. These cancers rely on oestrogen for their growth and can be treated using aromatase inhibitors that block the effects of the hormone.

The ICR and The Royal Marsden played a key role in the clinical development of aromatase inhibitors assessing their effectiveness over the years. The teams work in this field has been critical to understanding the biology of ER+ breast cancers and improving our knowledge of how these cancers become resistant to conventional hormone treatment.

Early trials involving Professor Mitch Dowsettfound that aromatase inhibitors were better than tamoxifen another type of hormone therapy for breast cancer at preventing the recurrence of ER+ breast cancers.

A seminal trial co-led by Professor Judith Bliss, an expert trial statistician and methodologist, demonstrated improved relapse-free survival in patients that switched to the aromatase inhibitor exemestane after two to three years of tamoxifen treatment compared with tamoxifen alone for five years. This trial played an instrumental role in changing practice guidelines for use of aromatase inhibitors in the clinic.

Professor Stephen Johnston, a consultant oncologist at The Royal Marsden, led the large-scale international MonarchE trialwhich aimed to identify new treatments that overcome resistance in ER+ breast cancer. The results showed that adding the drug abemaciclib a CDK4/6 inhibitor that prevents cell growth to hormone treatment significantly reduced the risk of the disease coming back in high-risk patients with early breast cancers.

The MonarchE trial was based on many years of research done at the ICR and The Royal Marsden and was a collaboration between both organisations, Eli Lilly and numerous international investigators. Abemaciclib was approved for adjuvant therapy by the FDA in the US in 2021 and just this month by the EMA.

Professor Bliss said, The ICR and The Royal Marsden bring together discovery science, clinical expertise and dedicated cancer specific trials methodology, which is ideal for designing scientifically robust, efficient and practice-changing clinical trials.

Professor Dowsett and his team also discovered an important biomarker Ki67, which marks newly divided cancer cells to evaluate the effectiveness of aromatase inhibitors in patients. The biomarker was subsequently developed into a test that is used to identify patients who might particularly benefit from hormone therapy.

The POETIC trialinvolved Professor Dowsett, Professor Bliss and Professor Ian Smith, and enrolled postmenopausal women who were planned to receive an aromatase inhibitor for five years following surgery. By starting the aromatase inhibitor two weeks before surgery and looking at how the Ki67 biomarker changed in patients tumours following the short-term therapy, the researchers were able to distinguish groups of patients with different risks of their cancer coming back.

Some patients started with a low level of the biomarker which stayed low after two weeks of treatment. The patients in this group had a very low chance of their cancer coming back during the next five years, with many of these patients able to be treated with aromatase inhibitor therapy alone. A minority of these patients were likely to still require chemotherapy if they exhibited certain high-risk features in their cancer.

For patients who had higher levels of the biomarker before treatment, assessing the levels again after two weeks of therapy showed that biomarker changes during that period affected the patients long-term outcome. Many of these patients had tumours that exhibited low levels of the biomarker following treatment. Patients whose biomarker levels stayed high following the brief exposure to aromatase inhibitors had the highest risk of their cancer coming back.

These findings helped to identify high-risk patients whose cancer was likely to come back and so required additional treatment above the current standard of care. This national trial engaged patients and doctors throughout the UK and helped to promote the desire for Ki67 biomarker testing as part of routine practice in the clinic.

Professor Johnston said, The pioneering work done by The Royal Marsden and the ICR is unrivalled elsewhere. Our close collaborations with the Cancer Research UK-funded Clinical Trials and Statistics Unitat the ICR and the scientists involved in the development of biomarkers made it possible to do the POETIC trial and plan the follow up POETIC-A trial, which started in 2020. These trials help to increase our understanding of the disease and how we can overcome resistance.

A measure of cancer treatment is not only how effective it is, but also how well tolerated it is by patients. Its important that research is used to find smarter and kinder treatments, and the joint team has excelled in this area.

The award recognises approaches that have led to de-escalation of breast cancer treatment. Long-standing research conducted by Professor John Yarnoldand Professor Bliss, and their wider teams, has revolutionised the way radiotherapy is delivered to people with breast cancer. This work was done in partnership with many other clinical leads at hospitals across the UK.

The findings from their clinical trials demonstrated that patients could be treated safely and effectively with fewer and bigger radiotherapy doses. Their remarkable discovery changed the treatment, for some patients, from being delivered in 25 doses over five weeks to just five doses over one week, reducing overall treatment time, the burden of that time on patients and hospital costs. This was particularly impactful during the Covid-19 pandemic when patients needed to receive treatment but minimise the time spent in hospitals.

Professor Bliss spoke about the impact of the radiotherapy trials saying, These trials investigated the balance of being able to keep recurrence rates down without causing more side effects. Our findings have been practice-changing and have had a great impact on the treatment pathways for breast cancer patients worldwide. They have also reduced inequalities by expanding access to the best treatment for patients in an impartial manner.

The team have also developed a test, known as a liquid biopsy, that detects tumour DNA circulating in the blood. By analysing samples of blood plasma from breast cancer patients to see if that tumour DNA is present, researchers can predict which patients are at risk of recurrence. This work, led by Professor Nick Turner, provides a less invasive way to assess patients and their response to therapy, avoiding the need for repeat tumour biopsies.

A recent phase II trial (plasmaMATCH), involving Professor Turner, Professor Bliss and Dr Alistair Ring, assessed the feasibility and clinical use of liquid biopsies in breast cancer patients it has shown promising results. The team have launched additional trials to further assess the potential use of liquid biopsies in guiding cancer therapy.

While most people with primary breast cancer, which hasnt spread, have a high survival rate because of the availability of effective treatments and the accessibility of tumours for surgical intervention, metastatic disease is still considered incurable.

Progress in treating advanced disease is urgently needed and the award recognised the discovery of molecular changes in breast cancer that drive some of the more aggressive behaviours in advanced breast cancer.

Professor Clare Isacke and her teams research focuses on how breast cancer cells interact with their environment during the early stages of metastatic colonisation. They have developed new ways to study advanced breast cancer using metastasis models in mice, which has provided important insights into how breast cancer cells adapt to survive in secondary sites and evolve to resist treatment. Their discoveries about how certain cells, called cancer associated fibroblasts, nourish tumour seedlings, have revealed potential therapeutic targets for advanced breast cancer.

Professor Pascal Meierand his team, whose work centres on cell death, have discovered proteins that regulate cell survival and inflammation. They are trying to change the way cancer cells die so that it activates the immune system and helps to fight the tumour cells more effectively. Their work uncovering how breast cancer cells escape death may help to develop new strategies for cancer therapies.

Image: Picture of the winning team from the ICR and The Royal Marsden. Credit:soora.co.uk

The ICR and The Royal Marsden have a close partnership that goes back many decades, which has been particularly productive for breast cancer research. Professor Johnston said, We are a close-knit team and have worked together for over 20 years. The regular dialogue between the basic scientists who are studying the biology of the disease and clinician scientists who are translating that into better treatments for patients facilitates easy transfer of knowledge. Our collaboration advances our understanding of breast cancer and also enables clinical trials to be set up relatively seamlessly.

Professor Lord also emphasised the unique partnership between the two organisations saying, Our close collaboration means any potential opportunity to translate is not lost. This ultimately means we can get new cancer treatments out to patients quickly.

Breast Cancer Now and Cancer Research UKfunded much of the teams research at the ICR. Professor Isacke said: The partnership between the ICR and The Royal Marsden really provides the best environment to do cancer research. Its a huge credit to the Breast Cancer Now charity, which set up a dedicated research centreat the ICR and created the space for us to do our research. They have continued to fund our research and support us all these years.

Speaking about the Team Science Award, Professor Tutt said, Its an amazing honour to receive this award. The AACR is one of the worlds biggest and most prestigious cancer research organisations and for them to have recognised a UK based team for the work weve done in breast cancer is a massive achievement.

Its unusual for this to be awarded to a team outside of the US. For us to have been that team, in fact for the second time now for the ICR, is a testament to what the ICR and its clinical partners at the Royal Marsden can achieve. We want to make fundamental discoveries that improve the outlook for our patients with breast cancer, and to be recognised for that, I think is as good as it gets.

He stressed, Each named member is a figurehead for a wider team who have been involved in the work, so this victory is shared by many.

Professor Lord agreed, It really does take an entire army of people to deliver all of that work. The AACR Team Science Award neatly illustrates that if you want to achieve things that make a real difference to people who actually have cancer, it needs a multidisciplinary team and involves an enormous amount of teamwork.

The winners of the AACR Team Science Award are Professor Alan Ashworth, Professor Judith Bliss, Professor Mitch Dowsett, Professor Clare Isacke, Professor Stephen Johnston, Professor Chris Lord, Professor Pascal Meier, Dr Alistair Ring, Professor Ian Smith, Professor Nick Turner, Professor Andrew Tutt, and Professor John Yarnold.

Here is the original post:
From bench to bedside and beyond: the team of scientists that transformed breast cancer treatment - The Institute of Cancer Research

Recommendation and review posted by Bethany Smith

Authorities said an arsonist likely burned down Knoxville's Planned Parenthood clinic on New Year's Eve in Dec. 2021.

KNOXVILLE, Tenn. It has been around 4 months since a Planned Parenthood medical clinic in East Knoxville was likely set on fire by an arsonist, according to the Knoxville Fire Department. It burned down on the morning of New Year's Eve in December 2021.

Leaders of the Planned Parenthood of Tennessee and North Mississippi branch said they planned to rebuild the clinic and welcome patients once again.

We will rebuild at our Cherry Street location," said Aimee Lewis, the vice president of external affairs. "We expect the design phase, which we are currently in, to take approximately 6 months and construction to take a year. While we work with our architects, builders and insurance to make this happen, we are exploring options to provide in-person services in some capacity in the meantime."

She said they are continuing to offer limited telehealth options and referrals for patients while trying to expand healthcare options by hiring more providers and staff.

In 2021, the clinic served almost 4,000 patients. More than 2,400 went to the medical facility for birth control and to test for sexually-transmitted diseases, while another 712 sought gender-affirming hormone therapy. Officials said 815 were there for abortion treatments.

The clinic had posted before burning down that it was closed for renovation "to enhance and expand our patient services."

Officials previously said they expected it would cost around $2.2 million to rebuild, in addition to the $2.2 million they had already spent on the renovation project the center burned down.

Recently, MacKenzie Scott donated a historic $275 million to support Planned Parenthood at the national level.

Regarding MacKenzie Scotts incredible generosity, Planned Parenthood of Tennessee and North Mississippi did not receive a donation," said Lewis. "However, this gift is a testament to the very strong health care network that the Planned Parenthood federation and its affiliates provide for its patients all over the country. Were excited to see what Ms. Scotts investment in our sister affiliates will do to bring care and education to the patients they serve.

Anyone with information about the arsonist or arsonists involved in the Knoxville branch's fire should reach out to KFD at 1-800-762-3017 or email them at KFDArson@Knoxvilletn.gov. They previously offered a reward of up to $10,000 for information.

More here:
'We will rebuild' | Knoxville Planned Parenthood leader expects year-and-a-half of work to reopen clinic - WBIR.com

Recommendation and review posted by Bethany Smith

CULTURAL INDOCTRINATION WAR.Recently, leftist activists and their allies in the media had a big success labeling a bill passed by the Florida Legislature as the "Don't Say Gay" bill. They claimed, without evidence, that the Republican-sponsored bill would ban the mention of homosexuality in Florida schools. In fact, the bill, now signed into law by Gov. Ron DeSantis, prohibited "classroom instruction" on "sexual orientation or gender identity" by teachers or other adults in kindergarten through third grade. It also said such instruction after third grade must be "age-appropriate" or "developmentally appropriate." In other words, it specifically allowed classroom instruction on such matters after third grade. Nevertheless, LGBTQIA+ activists called the bill "Don't Say Gay." Many media outlets and commentators picked it up immediately.

Now, just a month later, the same alliance is at it again. The Alabama Legislature has passed a bill banning hormone treatment, puberty blockers, and surgery for minors who say they want to change their gender. "Minors, and often their parents, are unable to comprehend and fully appreciate the risk and life implications, including permanent sterility, that result from the use of puberty blockers, cross-sex hormones, and surgical procedures," the Republican-sponsored bill says. "For these reasons, the decision to pursue a course of hormonal and surgical interventions to address a discordance between the individual's sex and sense of identity should not be presented to or determined for minors who are incapable of comprehending the negative implications and life-course difficulties attending to these interventions." A "minor," for the purposes of this measure, is defined in Alabama law as "a person who is under 19 years of age."

So the law bans certain drastic treatments and procedures for children 18 and under. And this is the headline of the New York Times story reporting it: "Alabama Lawmakers Approve Ban on Medical Care for Transgender Youth."

Subscribe today to the Washington Examiner magazine that will keep you up to date with what's going on in Washington. SUBSCRIBE NOW: Just $1.00 an issue!

A ban on medical care? If a "transgender youth," that is, 18 or under, breaks his or her leg or catches pneumonia or is diagnosed with cancer is that person denied medical care under the new law? Would it be illegal for a doctor to treat them? Obviously not. And is there a consensus that puberty blockers, hormone treatments, amputations, and other surgeries, irreversible actions, are appropriate "medical care" for young people age 18 and under? Those are questions raised by the New York Times headline.

NPR took a slightly different route, headlining its story "Alabama Legislature votes to ban gender-affirming medical care for transgender youth." The phrase "gender-affirming" has entered wide use quite recently and is a euphemism for medical procedures not to affirm but to change one's gender. For example, this explainer from the Mayo Clinic mentions "gender affirming genital surgical procedures, such as penile inversion vaginoplasty." For its part, the New York Times article describes the Alabama law as the criminalization of "gender-affirming surgeries."

The Biden White House is fully on board. On Thursday, press secretary Jen Psaki said, "To be clear, every major medical association agrees that gender-affirming healthcare for transgender kids is a best practice and potentially lifesaving." The Alabama law, Psaki continued, "would target trans youth with tactics that threaten to put pediatricians in prison if they provide medically necessary, lifesaving healthcare."

On March 31, the Biden administration released a statement celebrating what is called the "Transgender Day of Visibility." The statement used the word "affirm" or "affirming" 29 times. Some examples: The administration pledged to strengthen federal measures to "protect transgender youth against discrimination, including when those youth seek gender-affirming care." It pledged to emphasize "the positive impact of gender-affirming care on youth mental health." It pledged to confirm that "providing gender-affirming care is neither child maltreatment nor malpractice." It pledged to create an information bank to show why "gender-affirming care ... is important to transgender, nonbinary, and other gender expansive young people's well-being." It pledged to use the Justice Department to knock down laws like Alabama's by "reaffirming that transgender children have the right to access gender-affirming health care."

And so on. You get the idea. Not surprisingly, the phrase "gender-affirming" and its variants are showing up more and more in the media discussion of puberty blockers, hormone treatments, and surgery. Such measures are also benignly described as "medical care." And who could be against medical care? Who could respond negatively to a positive word like "affirming?"

Just like the "Don't Say Gay" situation, supporters of the Florida bill and now the Alabama bill, and other bills like them around the country, face a battle of language as well as substance. And with the current administration, the activist world, and much of the media arrayed against them, it is an uphill battle.

For a deeper dive into many of the topics covered in the Daily Memo, please listen to my podcast, The Byron York Show available on the Ricochet Audio Network and everywhere else podcasts can be found. You can use this link to subscribe.

See the original post here:
Cultural indoctrination war - Washington Examiner

Recommendation and review posted by Bethany Smith

Amryt Pharma plc

Amryt Announces Positive Long-Term Safety and Efficacy Data for Mycapssa (oral octreotide) from the 2nd Year of OPTIMAL Open Label Extension Study in Acromegaly Patients

Acromegaly patients were exposed to Mycapssa during the OPTIMAL Phase 3 Trial, including its open label extension (OLE), for a maximum treatment duration of 3.2 years

Study demonstrated that 100% of evaluable patients who entered the 2nd year OLE phase of the study as responders - insulin-like growth factor 1 (IGF-1) within normal limits - maintained their long-term biochemical response at the end of the study

IGF-1 levels were stably maintained within normal limits at the end of the OLE period (mean IGF-1 levels at baseline and at the end of the OLE were 0.92 and 0.84 respectively)

Growth hormone (GH) levels also improved at the end of the OLE period (mean GH levels at baseline and at the end of the OLE were 0.79 and 0.45 respectively)

Long-term safety profile of Mycapssa during the OLE was consistent with that observed in prior studies

DUBLIN, Ireland, and Boston MA, April 13, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today presents long-term safety and efficacy data from the 2nd year open-label extension (OLE) of its global Phase 3 OPTIMAL clinical trial that compared Mycapssa (octreotide capsules) to placebo for maintenance of biochemical response in patients with acromegaly. The OPTIMAL trial supported the approval of Mycapssa in the United States for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with injectable octreotide or lanreotide.

Susan L Samson, MD, PhD, at Mayo Clinic (Jacksonville, Florida), and lead investigator of the OPTIMAL study commented: These data together with the recently published positive results from the 3 years OLE period of the MPOWERED Phase 3 study further supports the long-term safety and efficacy of Mycapssa (oral octreotide) in acromegaly patients who were previously biochemically controlled on monthly injectable Somatostatin Receptor Ligands (iSRLs). The data showing that 100% of responders (IGF-1 within normal limits) maintained their response at the end of the 2nd year of the OLE, confirming the durability of response over time.

Story continues

Dr. Mark Sumeray, Chief Medical Officer of Amryt, commented: The OPTIMAL 2nd year OLE data show that acromegaly patients who were switched from iSRLs to Mycapssa may benefit from a daily oral treatment based on maintenance of long-term biochemical response.

OPTIMAL Phase 3 Trial Open-Label Long-Term Safety & Efficacy Data40 patients that completed the 9 months double-blind placebo controlled (DPC) core treatment phase elected to continue treatment with Mycapssa in the OPTIMAL open label extension study (20 patients that were originally randomized to Mycapssa and 20 that were randomized to placebo). Results from the first year were published previously and demonstrated that all patients who responded to Mycapssa (IGF-1 within normal limits) during the DPC period and enrolled in the OLE (n=14) completed the 48-week period and 93% (13/14) maintained their IGF-1 response within the normal limit at the end of this period. 32 patients continued treatment into the 2nd year of the OLE (18 of those originally randomized to Mycapssa during the DPC and 14 of those randomized to placebo).

Key 2nd year study outcomes included:

31 out of 32 patients (97%) of those enrolled to the 2nd year of the OLE completed 96 weeks in the OLE period

100% of evaluable patients, who entered the 2nd year OLE phase of the study as responders (IGF-1 within normal limits; N=17), maintained their long-term biochemical response at the end of the study. The average IGF-1 levels of enrolled patients were stably maintained within the normal limits at the end of the OLE period (mean IGF-1 levels at baseline OLE and at the end of the OLE were 0.92 and 0.84 respectively).

93% of all patients who entered the 2nd year OLE phase (N=32) were responders at the end of the 96 weeks OLE

The average GH levels of enrolled patients improved at the end of the OLE period (mean GH levels at baseline OLE and at the end of the OLE were 0.79 and 0.45 respectively)

Acromegaly patients were exposed to Mycapssa during the OPTIMAL study (including its OLE phase), for a median treatment duration of 2.1 years and a maximal exposure of 3.2 years

Patients in the OLE demonstrated a median compliance rate of 98% over this period of time

The long-term safety profile of Mycapssa during the OLE, was consistent with the safety profile observed during previous studies with Mycapssa with no new safety signals with long-term exposure

About the OPTIMAL Phase 3 TrialThe OPTIMAL trial (NCT03252353) was a randomized, double-blind, placebo-controlled, nine-month Phase 3 clinical trial of octreotide capsules in 56 adult acromegaly patients whose disease was biochemically controlled by injectable somatostatin analogs (octreotide or lanreotide). Patients were randomized on a 1:1 basis, to octreotide capsules or placebo. The primary endpoint of the trial was the proportion of patients who maintained their biochemical response (IGF-1 levels 1.0 ULN), at the end of the nine-month, double-blind, placebo-controlled period. Hierarchical secondary endpoints included: (i) proportion of patients who maintain GH response at 9 months; (ii) time to loss of response; and (iii) proportion of patients requiring reversion to prior treatment. The OPTIMAL study met the primary endpoint and all secondary endpoints which led to the US approval of Mycapssa, the first oral somatostatin analog, for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with injectable octreotide or lanreotide.

FDA APPROVED INDICATION AND USAGEMycapssa delayed-release capsules, for oral use, is a somatostatin analog indicated for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.

IMPORTANT SAFETY INFORMATIONWARNINGS AND PRECAUTIONSMycapssa can cause problems with the gallbladder. Monitor patients periodically. Discontinue if complications of cholelithiasis are suspected. Blood sugar, thyroid levels, and vitamin B12 levels should be monitored and treated accordingly. Bradycardia, arrhythmia, or conduction abnormalities may occur. Treatment with drugs that have bradycardia effects may need to be adjusted.

The full US Prescribing Information for Mycapssa is available at http://www.mycapssa.com.

About AcromegalyAcromegaly typically develops when a benign tumor of the pituitary gland produces too much growth hormone, ultimately leading to significant health problems. Common features of acromegaly are facial changes, intense headaches, joint pain, impaired vision and enlargement of the hands, feet, tongue and internal organs. Serious health conditions associated with the progression of acromegaly include type 2 diabetes, hypertension, respiratory disorders and cardiac and cerebrovascular disease. Amryt estimates that approximately 8,000 adult acromegaly patients are chronically treated with somatostatin analog injections in the United States.

About Amryt Amryt is a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing innovative treatments to help improve the lives of patients with rare and orphan diseases. Amryt comprises a strong and growing portfolio of commercial and development assets.

Amryts commercial business comprises three orphan disease products metreleptin (Myalept/ Myalepta); oral octreotide (Mycapssa); and lomitapide (Juxtapid/ Lojuxta).

Myalept/Myalepta (metreleptin) is approved in the US (under the trade name Myalept) as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy (GL) and in the EU (under the trade name Myalepta) as an adjunct to diet for the treatment of leptin deficiency in patients with congenital or acquired GL in adults and children two years of age and above and familial or acquired partial lipodystrophy (PL) in adults and children 12 years of age and above for whom standard treatments have failed to achieve adequate metabolic control. For additional information, please follow this link.

Mycapssa (octreotide capsules) is approved in the US for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. Mycapssa is the first and only oral somatostatin analog approved by the FDA. Mycapssa has also been submitted to the EMA and is not yet approved in Europe. For additional information, please follow this link.

Juxtapid/Lojuxta (lomitapide) is approved as an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the rare cholesterol disorder, Homozygous Familial Hypercholesterolaemia ("HoFH") in the US, Canada, Colombia, Argentina and Japan (under the trade name Juxtapid) and in the EU, Israel, Saudi Arabia and Brazil (under the trade name Lojuxta). For additional information, please follow this link.

Amryt's lead development candidate, Oleogel-S10 is a potential treatment for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no approved treatment. Filsuvez has been selected as the brand name for Oleogel-S10. The product does not currently have regulatory approval to treat EB.

Amryts pre-clinical gene therapy candidate, AP103, offers a potential treatment for patients with Dystrophic EB, and the polymer-based delivery platform has the potential to be developed for the treatment of other genetic disorders.

Amryt also intends to develop oral medications that are currently only available as injectable therapies through its Transient Permeability Enhancer (TPE) technology platform. For more information on Amryt, including products, please visit http://www.amrytpharma.com.

Forward-Looking StatementsThis announcement may contain forward-looking statements and the words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. The forward-looking statements in this announcement are based on numerous assumptions and Amryt's present and future business strategies and the environment in which Amryt expects to operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These statements are not guarantees of future performance or the ability to identify and consummate investments. Many of these risks and uncertainties relate to factors that are beyond Amryt's ability to control or estimate precisely, such as future market conditions, the course of the COVID-19 pandemic, currency fluctuations, the behaviour of other market participants, the outcome of clinical trials, the actions of regulators and other factors such as Amryt's ability to obtain financing, changes in the political, social and regulatory framework in which Amryt operates or in economic, technological or consumer trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. No person is under any obligation to update or keep current the information contained in this announcement or to provide the recipient of it with access to any additional relevant information that may arise in connection with it. Such forward-looking statements reflect the Companys current beliefs and assumptions and are based on information currently available to management.

ContactsJoe Wiley, CEO / Rory Nealon, CFO/COO, +353 (1) 518 0200, ir@amrytpharma.comTim McCarthy, LifeSci Advisors, LLC, +1 (212) 915 2564, tim@lifesciadvisors.com

See the original post here:
Amryt Announces Positive Long-Term Safety and Efficacy Data for Mycapssa (oral octreotide) from the 2nd Year of OPTIMAL Open Label Extension Study in...

Recommendation and review posted by Bethany Smith

Your elevated hematocrit/hemoglobin might well be directly related to your TRT. If so, there are ways to address that. However, your TRT might only be partly to blame as there are other conditions that can either contribute to high hematocrit/hemoglobin or even give false readings.

Depending on your situation, here are several ways to address high levels of hematocrit/hemoglobin:

This is the most obvious solution to elevated hematocrit, but it's probably also the least popular. Hardly any man wants to use less testosterone and give up any of the increased energy, sexuality, and muscularity that the hormone has gifted him. But truth be told, a lot of men are probably taking more than they need. The standard TRT clinic dosage is 200 mg. a week, which is, frankly, equivalent to a mild steroid cycle.

A study conducted by the Department of Urology at University of California found that subcutaneous (subQ) injections (under the skin rather than into the muscle) led to higher levels of free T, along with evidence of subQ being physiologically superior to IM shots in several other important ways.

Men who received subQ injections of testosterone exhibited the following:

The second result is the kicker. Since subQ injections led to a 41% reduction in hematocrit levels, you could theoretically use the same dosage you use for intramuscular injections. Of course, given that subQ injections led to a 14% increase in total T, you might just use a lesser dosage anyhow and further reduce hematocrit while retaining all the positive effects of your TRT.

Studies have shown that testosterone creams and gels raise hematocrit less than intramuscular testosterone injections.

This is the standard go-to treatment for high hematocrit. Every pint donated has been shown to decrease hematocrit by about 3 points. Unfortunately, you'd likely have to continue to periodically donate blood if you hadn't adopted any other hematocrit-lowering strategies.

That being said, there's some evidence that hematocrit levels stabilize after donating blood five times. Whether that's universally true is unlikely.

You can donate blood to places like the Red Cross or have your doctor perform what's known as a "therapeutic blood draw." Be careful not to donate too often, though. Giving a pint of blood more than every two and a half months or so may lead to long stints of fatigue.

High hematocrit readings sometimes occur because the patient was simply dehydrated, making it appear that the concentration of red blood cells was higher than it really was.

Of course, one simple way to determine whether your high hematocrit was caused by dehydration is to do a little simple math: hematocrit must always be three times the value of hemoglobin. If it's lower (Hct<3 x Hb), you're over-hydrated. If it's higher (Hct>3 x Hb), you're dehydrated. Either way, you're getting a false value because of your hydration status.

Red meats are high in heme iron (the type of iron found only in animal tissues), which is more efficiently absorbed than non-heme iron (the type found in whole grains, nuts, seeds, legumes, and leafy greens), and ingesting it can raise hemoglobin and, subsequently, hematocrit.

Sleep apnea is a medical condition where patients suffer from fragmented sleep. They literally stop breathing from 10 to 50 seconds multiple times throughout the night.

As a result of this interrupted breathing/sleep, patients experience poor oxygen saturation, which forces the body to produce more red blood cells and more hemoglobin.

Evidence suggests that curcumin binds to ferric acid in the digestive system, thus reducing hemoglobin levels. Be sure to use micellar curcumin which is 95 times more bioavailable than regular curcumin with piperine.

If you've got high hematocrit/hemoglobin AND have high blood pressure, ask your doctor to consider switching your high blood pressure medicine to Losartan. It's been used by physicians since the early 2000s to bring down hematocrit in kidney transplant patients and patients with chronic obstructive pulmonary disease (COPD).

See original here:
TRT Side Effects: The Big One to Avoid - T NATION

Recommendation and review posted by Bethany Smith

Imagine your 13-year-old daughter is depressed and withdrawn and then, one day, she tells you shes trans and will, henceforth, be known as Sean. You must no longer call her by her dead name. Even the most liberal parent may swallow hard and ask her (them) to have counselling with an experienced psychologist who can explore those feelings before the teenager embarks on drastic hormone treatment.

Thats a loving reaction, in my book. Astonishingly, in some countries it would be illegal. Therapists are forbidden to try and find out if anything else may lie behind a young persons misery in their own body. According to trans activists, talking therapies are the same as conversion therapy, an abhorrent practice which puts pressure on a gay boy or girl to renounce their sexuality.

Stonewall, the LGBTQ campaign group, insists that only affirmation is acceptable. You are not allowed to suggest your child is confused or to point out that there has been an extraordinary increase in girls seeking to transition from female to male or that many of those girls have autism. Nor that some kids who think they are trans have been bullied for being gay.

I agree with Debbie Hayton, a transwoman and campaigner, who says that the denial of meaningful therapy for vulnerable youngsters is chilling. But loving parents who make the same objection are branded transphobic.

This is the background to the Governments U-turn in which it excluded trans people from legislation banning conversion therapy. The Prime Minister drew a crucial distinction, saying, There are complexities and sensitivities when you move from the area of sexuality to the question of gender ... I dont think its reasonable for kids to take decisions about their gender without a parents involvement.

Boris is right. It isnt reasonable and nor is it kind. Kids who are in a distressed state can fixate on one solution to all their problems. Society owes them more than a reckless rush down the clinic for hormones which will wreck their fertility.

How tragic that this personal matter should become a political football. Terrified of their ideological commissars, Labour MPs look like complete wallies as they refuse to confirm or deny whether a person with a penis can be a woman. Angela Rayners tortuous answer to that vexed question sounded like a stoned sociology lecturer speaking Swahili. Its encouraging to see women across the spectrum, from Mumsnet to radical feminists, uniting against this insulting nonsense.

Ironically, many trans people do not want all this aggro on their behalf. Its frightening. A wise friend of mine whose partner transitioned successfully says, Every family starts from a position of denial and sadness. Sometimes they are right, sometimes they are wrong. Exactly. Some children will turn out to be correct in believing they would feel more themselves as another gender. For others, gender dysphoria may have been a peg on which to hang all the neuroses which are so common in that difficult phase of life.

Those young people all deserve loving support and proper counselling. What they dont need is fearful affirmation as they make the biggest, potentially most irreversible, decision of their lives.

Much amusement here at Pearson Towers after a headache and feeling tired were added to the official list of Covid symptoms. Isnt that the chronic and irreversible condition called Being Over 50?

Before half the population decided to throw a Covid sickie (Cickie?), Sajid Javid said that he personally would first reach for the Nurofen and go into work. I should think so too. The Health Secretary has got a six-million-long hospital waiting list to tackle.

I wonder, is Mr Javid aware of the further delays that an ongoing Covid fixation is causing in the NHS? One surgeon emailed me to express his alarm. A 66-year-old patient had arrived in hospital for heart surgery. Just hours before the operation, the poor man tested positive for Covid. Although he was not displaying any serious symptoms except, possibly, feeling tired the operation was cancelled.

That patients risk of death from surgical intervention has just risen to 90 per cent from an estimated 30 per cent directly because of the delay, fumes my source. I cannot believe that so many allegedly intelligent people are unable to make a sound judgment on the risk-benefit ratio of what is now just a flu.

Covid is no longer likely to kill you. But hospitals cancelling your operation or urgent appointment may well. The NHS needs to get a grip. We have nothing to fear but the fearful.

See more here:
It's cruel to deny trans children the chance to think again - The Telegraph

Recommendation and review posted by Bethany Smith

Eating a balanced diet and taking high-quality supplements can help support your body as you stop taking the pill.

Image Credit: LIVESTRONG.com Creative

What Really Happens to Your Body When examines the head-to-toe effects of common behaviors, actions and habits in your everyday life.

The side effects of starting hormonal birth control are pretty widely discussed. But there's a little more mystery about what happens to your body when stopping birth control.

Birth control pills, also known as oral contraceptive pills, are the second most common type of contraceptive method as of 2019 (the latest data available), per the Centers for Disease Control and Prevention (CDC). If you've been thinking about stopping birth control after being on the pill for years, you should know that it's safe to stop at any time, according to the Mayo Clinic. But you should expect your body to go through some changes.

Here's the scoop on the side effects of stopping birth control pills and tips for taking care of yourself as you make the transition.

When to Stop Birth Control Pills

There are several reasons why someone might want to stop using birth control pills. According to Felice Gersh, MD, ob-gyn and the founder/director of Integrative Medical Group of Irvine, those reasons include:

Your Period Could Become Irregular

While some people who menstruate go back to their normal periods soon after stopping birth control pills, other people may have irregular periods for a while.

"Even if ovulation resumes during the first cycle post-pill, there's no guarantee the next few cycles will be regular. In fact, it can take up to a year for their cycles to go back to regular," says Kerry-Anne Perkins, DO, ob-gyn and member of the medical review board of Women's Health Interactive. "This is true for both types of pills, progesterone or estrogen-free and combined hormonal, which has both estrogen and progesterone."

And if you took birth control in order to regulate your menstrual cycle, there's a chance that previous unpleasant period-related symptoms may make a return, she notes.

You may also notice a change in the flow and duration of your period, per the Cleveland Clinic. It may be longer and heavier birth control pills typically give you shorter and lighter periods.

Your Fertility Levels Could Be Lower

It's valid to have concerns about how your fertility may be affected by discontinuing birth control pills, especially if you are trying to become pregnant.

A July 2018 meta-analysis in Contraception and Reproductive Medicine found stopping contraceptive use doesn't significantly delay or negatively affect fertility.

But your fertility levels may also be lower than they were when you started taking birth control pills. "If you have been on birth control for many years, your fertility has naturally declined and may be significantly lower than when you started the birth control," Dr. Perkins says.

When stopping the pill, be sure to use a backup method of contraception if you aren't looking to get pregnant at all or right away, per the Cleveland Clinic.

You Could Lose or Gain Weight

The belief that oral contraceptives commonly cause you to gain weight is a longstanding one, per a January 2014 study in the Journal of Women's Health.

But researchers of the study found birth control pills weren't linked to short-term changes in weight or body composition after observing 150 people assigned female at birth (AFAB) with both normal weight and obesity who used oral contraception over three to four months.

Typically, the pill doesn't cause more than a pound of weight gain per year, according to the Cleveland Clinic.

There are chances that you can lose or gain weight after you stop taking the pill, though. "Some women retain water while on the pill, so if this is you, you may drop a couple of pounds after quitting it," Dr. Perkins says. "Others could retain water after quitting the pill, due to some temporary hormonal imbalances. Again, it shouldn't be more than a couple of pounds."

It's also possible to experience changes in appetite due to hormonal shifts, Perkins notes, that could in turn contribute to weight changes.

When to Talk to Your Doctor

Talk to your doctor if you have questions or concerns about what to expect when stopping birth control pills, per the Cleveland Clinic. That's also a good time to discuss how being off of the pill will affect any prior conditions you have.

You May Have Acne or Hair Loss

You have hormonal changes to thank for any adverse skin and hair-related side effects you may experience after you come off birth control pills. Quitting birth control pills leads to a temporary hormonal imbalance, according to Dr. Perkins.

"For example, acne is fairly common in the first few months post-pill," she says. Experiencing hair loss or a condition called hirsutism (excessive facial hair) is also possible.

You Might Experience Mood Shifts

Most people won't experience significant emotional changes related to stopping the pill; most of the effects are physical, per Jefferson Health. But if you experienced mood swings or emotional instability on birth control, those things may stop post-pill.

On the flip side, if you were prone to depression, anxiety and mood swings before using birth control pills, those conditions may return when you nix oral contraception, according to Oschner Health.

Your Sex Drive May Change

A September 2012 review in The Journal of Sexual Medicine found a small correlation between the use of hormonal contraceptives and decreased libido, however research shows there are mixed results overall on how hormonal birth control affects your sex drive.

If you experienced lower desire while on the pill, you could find yourself feeling more sexual than usual after you stop taking it. "After quitting the pill, you may also experience changes in your libido usually higher libido, especially around ovulation," Dr. Perkins says.

Stopping Other Types of Hormonal Birth Control

Here are some potential side effects of stopping other types of hormonal birth control, according to Dr. Perkins:

Tips to Help Make Stopping the Pill Easier

Many of the side effects of discontinuing your birth control pill are temporary, but there are things you can do to help ease them.

1. Take a High-Quality Multivitamin

A September 2016 study in The Journal of Clinical Endocrinology and Metabolism found an association between higher vitamin D levels and estrogen-containing contraceptive use among more than 1,600 people identified in the study as African American women.

It may be beneficial to focus on naturally increasing your nutrient levels after you're off the pill. Some ways to raise your vitamin D levels, per the Mayo Clinic, include:

Dr. Gersh also recommends supplementing if you can't fit enough crucial nutrients from your diet alone. "Taking a high-quality multivitamin is key. Be sure it contains methyl B12, methyl folate, selenium and the usual array of vitamins," she says. "Extra magnesium would be of benefit, along with omega-3s and vitamin D."

2. Finish Out Your Current Pill Cycle

While you can quit the pill cold turkey, it may be best to finish out your current pill pack before stopping altogether.

You can expect to have your period within a few days after stopping the pill if you stop in the middle of the current pill cycle, according to the Cleveland Clinic.

Try to finish out your current round of pills, if possible, to avoid messing with your period.

A balanced diet can help as you transition away from birth control pills. Eating well is especially important if your appetite is affected by stopping the pill. For example, you may experience cravings.

"Pay attention to those cravings and try to eat a healthy and balanced diet to minimize them, and you shouldn't have weight issues," Dr. Perkins says.

Original post:
What Happens When You Stop Taking Birth Control Pills - Livestrong

Recommendation and review posted by Bethany Smith

The report titled Adenomyosis Treatment market offers a primary overview of the Adenomyosis Treatment industry covering different product definitions, classifications, and participants in the industry chain structure. The quantitative and qualitative analysis is provided for the global Adenomyosis Treatment market considering competitive landscape, development trends, and key critical success factors (CSFs) prevailing in the Adenomyosis Treatment industry.

A number of estimations and calculations have been included in this market report by assuming a definite base year and the historic year. The report describes estimations of CAGR values, market drivers, and market restraints about this industry which is helpful for businesses in deciding upon numerous strategies. With this market report, you can effectively gain a holistic view of the market and then also benchmark all the companies in this industry. To win the competition in the global marketplace, going for this global market research report is necessary. This market report makes your organization armed with information produced by sound research methods.

Get Access to PDF Sample of Global Adenomyosis Treatment Market Research Report with Opportunities and Strategies to Boost Growth- COVID-19 Impact and Recovery @: https://globalmarketvision.com/sample-request/158723

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the market which would mention How the Covid-19 is affecting the Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Covid-19 Impact on Key Regions and Proposal for Adenomyosis Treatment Market Players to Combat Covid-19 Impact.

Some of the key players in the Global Adenomyosis Treatment Market are Company Coverage (Company Profile, Sales Revenue, Price, Gross Margin, Main Products, etc.):

Bayer AG, Ferring B.V, Johnson & Johnson, Novartis, Merck, Pfizer.

Global Adenomyosis Treatment Market Segmentation:

Market Segmentation: By Type

Anti-inflammatory drugsHormone medicationsOther

Market Segmentation: By Application

HospitalClinicOthers

This comprehensive report provides:

COVID-19 Impact

Report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Retro Scooters Market in 2022.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

Reasons to Purchase the report:

Table of Content (TOC):

Chapter 1 Introduction and Overview

Chapter 2 Industry Cost Structure and Economic Impact

Chapter 3 Rising Trends and New Technologies with Major key players

Chapter 4 Global Adenomyosis Treatment Analysis, Trends, Growth Factor

Chapter 5 Adenomyosis Treatment Application and Business with Potential Analysis

Chapter 6 Global Adenomyosis Treatment Segment, Type, Application

Chapter 7 Global Adenomyosis Treatment Analysis (by Application, Type, End User)

Chapter 8 Major Key Vendors Analysis of Adenomyosis Treatment

Chapter 9 Development Trend of Analysis

Chapter 10 Conclusion

Complete report on Adenomyosis Treatment Market report spread across 150+ pages, list of tables & figures, profiling 10+ companies. Read Detailed Index of Full Research Study at @ https://globalmarketvision.com/checkout/158723/single_user_license

If you have any special requirements, please let us know and we will offer you the report at a customized price.

About Global Market Vision

Global Market Vision consists of an ambitious team of young, experienced people who focus on the details and provide the information as per customers needs. Information is vital in the business world, and we specialize in disseminating it. Our experts not only have in-depth expertise, but can also create a comprehensive report to help you develop your own business.

With our reports, you can make important tactical business decisions with the certainty that they are based on accurate and well-founded information. Our experts can dispel any concerns or doubts about our accuracy and help you differentiate between reliable and less reliable reports, reducing the risk of making decisions. We can make your decision-making process more precise and increase the probability of success of your goals.

Contact Us

Sarah Ivans | Business Development

Phone: +1-3105055739

Email: [emailprotected]

Global Market Vision

Website: http://www.globalmarketvision.com

Here is the original post:
Adenomyosis Treatment Market Analysis and Demand with Future Forecast to 2029 | Bayer AG, Ferring BV, Johnson & Johnson, Novartis Political Beef...

Recommendation and review posted by Bethany Smith

Its mid-afternoon on a mild spring day at Artemisia Clinic in Taos. Dr. Clara Wetmore, a doctor of Oriental Medicine, is treating Amy Dondanville, who has difficulty sleeping. Soothing music plays and fragrant herbs in orderly rows surround the treatment table of the well-lit clinic.

Wetmore consults with Dondanville and then checks her pulse at various points on her body, asking questions in a quiet voice, How is your stress level? Energy level? She asks how much caffeine Dondanville consumes.

Dondanville is experiencing a high level of stress, having just returned to her job as a clinical social worker after being gone for three weeks. She reports that she is not sleeping well and feels more frantic, like she is running on adrenaline that causes her to crash. She has removed most caffeine from her diet, drinking just one cup of black tea a day.

While Dondanville relaxes on the treatment table, Wetmore places needles in various parts of her body: her forehead, wrist, midsection and lower legs. I place needles at specific points along the relevant or affected meridians, based on symptoms, presentation and pulse diagnosis. Each point has unique indications, and I pick the points that relate to or address the symptoms and underlying health concerns, Wetmore explained. Today, she is inserting needles to help calm the mind, as well as reduce racing thoughts, anxiety, pain and insomnia. As the needles are placed, Dondanville explains that shes not feeling any pain, although sometimes she experiences a sensation.

Wetmore uses another tool, known as an ear or auricular seed, which is a tiny stainless steel pellet with a latex-free adhesive patch. Ear seeds are a type of auriculotherapy rooted in Chinese medicine. They're meant to promote comfort and relaxation and have become very popular in the West in recent years, despite some disagreement among medical professionals as to their efficacy. Occasionally, Wetmore uses gold pellets, depending on the treatment, or even small pellets with crystals on the top that look like little earrings if brought in by a patient.

Wetmore cleans and disinfects the ear and then places the tiny pellets in specific spots on the left ear that are tender, indicating trouble somewhere in the body. Dondanville will wear them for a week, after which they fall out or she will remove them. The ear seeds do their work while in place, Wetmore says, and their effectiveness can be increased by periodically pressing on them. Right now, I am placing an ear seed to regulate the nervous system and treat an insomnia point," she explains. "I also checked the liver point, usually aggravated by stress but that spot wasnt tender, so I am moving on to the heart spot which is calming to the mind.

Dondanville is experiencing difficulty powering down and falling asleep, which is her most common sleep struggle, although she does sometimes wake up in the middle of the night and have a hard time going back to sleep. She usually comes in weekly, but since she has been out of town, this is her first appointment in almost a month. She says, Ive had chronic sleep problems since I was a kid; its always been a struggle for me. The practice of coming regularly allows me to connect with my body and speak to what is specifically happening with my digestion, sleep, mood and energy levels. The act of reflecting is helpful itself. When accessing treatment regularly, I find I can fall asleep with great ease, which I wasnt previously able to achieve.

Wetmore also gives Dondanville a Chinese herbal formula for sleep. At the beginning of treatment, she was taking three to four doses per night and that has been reduced to one or none. This is what I want for all my patients: to get to the point where their bodies remember how to sleep without external help, says Wetmore.

Dondanville has been seeing Wetmore for about two and a half years. She sought Wetmore out for help with another issue, but through the comprehensive check-ins done at each appointment, the two discovered the extent of Dondanvilles sleep disturbances. The practice of attending appointments and engaging in reflection has created a sense of mindfulness and awareness about what is happening outside appointments and brought a deeper sense of noticing about which routines and habits nurture my body and which ones harm them, reflects Dondanville.

When asked what advice she would give to people struggling with sleep problems, Dondanville recommends that people become aware of what content is stimulating to the brain in a negative way, whether it be watching TV, listening to audio recordings or scrolling on the phone.

According to a study by Harvard Medical School, the blue light emitted by smartphones "can affect your sleep and potentially cause disease." The study notes a well-known fact about the brain that the absence of light signals to the brain to shut down for sleep and the presence of light triggers wakefulness. As such, turning down any bright lights before bed can help people to achieve deeper sleep. Conversely, exposure to daylight upon waking can boost alertness and mood.

Wetmore added, Id suggest that people establish a routine that cues the body that it is time to move towards sleep, which might be stretching, taking a bath or shower, or applying cream to nurture the body.

Sleep disorders and effective treatment

Wetmore opened her practice five years ago. She earned a Master's of Science in Oriental Medicine degree from the Southwest Acupuncture College in Santa Fe and is licensed by the state and certified nationally. For the best results, she sees patients on a regular basis, but even a single treatment can help. One new patient who was skeptical of acupuncture came to see Wetmore to get help with her racing thoughts. Wetmore treated her with acupuncture, ear seeds and an herbal formula. When Wetmore saw the patient next, she had gone from sleeping for about an hour a night to sleeping seven hours. Sometimes its dramatic like that, and other times it can take weeks or months to see results like hers, says Wetmore.

More than 100 different types of sleep disorders have been identified, according to the Sleep Foundation. Wetmore sees many of them at her clinic. People come to me with sleep issues ranging all over the insomnia spectrum; some who cant fall asleep, some who cant stay asleep or wake up too early, some light sleepers, some with crippling nighttime anxiety, some who cant turn their minds off at night," she says. "Some patients sleep for a few minutes per night if at all some for a few hours and some just dont get quite enough for their particular needs. The causes range from trouble sleeping due to menopausal or perimenopausal hormone shifts, which account for about half of her patients, while others are dealing with stress, anxiety, trauma, grief, pain or other issues. Sometimes, there is no obvious cause.

Because sleep disorders are so unique to each individual, being able to tailor acupuncture treatments and herbal formulas to each patients needs is hugely important in my work, says Wetmore. My goal is to regulate the sleep cycle so that patients dont need to take herbs and supplements forever to get a good nights sleep. Its like giving a gentle nudge and reminder for the body to remember how to do such a fundamental and necessary regenerative process on its own. Another advantage is that I spend a lot of time with each patient, so I really get to know each persons life, physical health and emotional health, giving me the insight to treat very specifically.

As part of her approach, Wetmore checks for any medications being taken by the patient to make sure there wont be interactions between the medications and herbs she recommends for sleep. In addition to making recommendations about nutrition, Wetmore refers patients to other needed services, such as therapy, meditation, exercise, primary care and other physicians.

When asked how her approach is different than a medical doctors might be, Wetmore said, In some ways, my approach probably isnt all that different than that of Western medicine; were all trying to help people feel better, and are using the tools, knowledge and skillsets we have. I have tremendous respect for my medical colleagues, and although folks dont always expect it, Im very much in support of Western medicine and science, and love to work in tandem with my patients other providers.

The questions of how much sleep we need as humans and how the lack of sleep impacts our health are the subjects of numerous studies over the past few years. In his 2017 book, Why We Sleep, Matthew Walker, Ph.D., professor of neuroscience and psychology at UC Berkeley and the director of the Center for Human Sleep Science, reports that two-thirds of the adults in developed nations do not get the full eight hours of recommended sleep. Through his research, he has pioneered work showing that insufficient sleep depresses the immune system, doubles risk of cancer, adds to weight gain and is a key factor in whether or not a person will develop Alzheimers disease. To find out more and see tips for better sleep, visit masterclass.com/articles/matthew-walker-on-improving-sleep-quality. There are also several free podcasts featuring Walker that delve into his research.

Here is the original post:
Chinese medicine and the pursuit of a good night's sleep - taosnews

Recommendation and review posted by Bethany Smith

New York, United States A2Z Market Research published new research on Global Osteoporosis Treatment covering the micro-level of analysis by competitors and key business segments (2022-2029). The Global Osteoporosis Treatment explores a comprehensive study on various segments like opportunities, size, development, innovation, sales, and overall growth of major players. The research is carried out on primary and secondary statistics sources and it consists of both qualitative and quantitative detailing.

Some of the Major Key players profiled in the study are Merck & Co AGNovartis AGEli Lilly and CompanyAmgen, Inc.Allergan PlcActavis Plc.Pfizer, Inc.GlaxoSmithKline Pharmaceutical Ltd.F. Hoffmann La Roche Ltd.Novo Nordisk A/STeva Pharmaceuticals Industries Ltd.

Get PDF Sample Report + All Related Table and Graphs @:

https://www.a2zmarketresearch.com/sample-request/584373

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Osteoporosis Treatment market. This report is a consolidation of primary and secondary research, which provides market size, share, dynamics, and forecast for various segments and sub-segments considering the macro and micro environmental factors. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitutes, and the degree of competition prevailing in the market.

Key market aspects are illuminated in the report:

Executive Summary: It covers a summary of the most vital studies, the Global Osteoporosis Treatment market increasing rate, modest circumstances, market trends, drivers and problems as well as macroscopic pointers.

Study Analysis: Covers major companies, vital market segments, the scope of the products offered in the Global Osteoporosis Treatment market, the years measured, and the study points.

Company Profile: Each Firm well-defined in this segment is screened based on a products, value, SWOT analysis, their ability and other significant features.

Manufacture by region: This Global Osteoporosis Treatment report offers data on imports and exports, sales, production and key companies in all studied regional markets

Global Osteoporosis Treatment Market Segmentation:

Market Segmentation: By Type

BisphosphonatesParathyroid Hormone TherapyCalcitoninSelective Estrogen Inhibitors Modulator (SERM)

Market Segmentation: By Application

HospitalsClinicOthers

Market Segmentation: By Geographical Analysis

The Middle East and Africa (GCC Countries and Egypt)North America (the United States, Mexico, and Canada)South America (Brazil etc.)Europe (Turkey, Germany, Russia UK, Italy, France, etc.)Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Get Special pricing with up to 30% Discount on the first purchase of this report @:

https://www.a2zmarketresearch.com/discount/584373

The cost analysis of the Global Osteoporosis Treatment Market has been performed while keeping in view manufacturing expenses, labor cost, and raw materials and their market concentration rate, suppliers, and price trend. Other factors such as Supply chain, downstream buyers, and sourcing strategy have been assessed to provide a complete and in-depth view of the market. Buyers of the report will also be exposed to a study on market positioning with factors such as target client, brand strategy, and price strategy taken into consideration.

Key questions answered in the report include:

Table of Contents

Global Osteoporosis Treatment Market Research Report 2022 2029

Chapter 1 Osteoporosis Treatment Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Osteoporosis Treatment Market Forecast

Buy the Full Research Report of Global Osteoporosis Treatment Market @: :

https://www.a2zmarketresearch.com/checkout

If you have any special requirements, please let us know and we will offer you the report as you want. you can also get individual chapter-wise sections or region-wise report versions like North America, Europe or Asia.

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

sales@a2zmarketresearch.com

+1 775 237 4147

Continued here:
Osteoporosis Treatment Market See Huge Growth for New Normal | Merck and Co AG, Novartis AG, Eli Lilly and Company Bloomingprairieonline -...

Recommendation and review posted by Bethany Smith

The SARS-CoV-2 virus can infect specialized pacemaker cells that maintain the hearts rhythmic beat, setting off a self-destruction process within the cells, according to a preclinical study co-led by researchers at Weill Cornell Medicine, NewYork-Presbyterian and NYU Grossman School of Medicine. The findings offer a possible explanation for the heart arrhythmias that are commonly observed in patients with SARS-CoV-2 infection.

In the study, reported March 8 in Circulation Research, the researchers used an animal model as well as human stem cell-derived pacemaker cells to show that SARS-CoV-2 can readily infect pacemaker cells and trigger a process called ferroptosis, in which the cells self-destruct but also produce reactive oxygen molecules that can impact nearby cells.

This is a surprising and apparently unique vulnerability of these cellswe looked at a variety of other human cell types that can be infected by SARS-CoV-2, including even heart muscle cells, but found signs of ferroptosis only in the pacemaker cells, said study co-senior author Dr. Shuibing Chen, the Kilts Family Professor of Surgery and a professor of chemical biology in surgery and of chemical biology in biochemistry at Weill Cornell Medicine.

Arrhythmias including too-quick (tachycardia) and too-slow (bradycardia) heart rhythms have been noted among many COVID-19 patients, and multiple studies have linked these abnormal rhythms to worse COVID-19 outcomes. How SARS-CoV-2 infection could cause such arrhythmias has been unclear, though.

In the new study, the researchers, including co-senior author Dr. Benjamin tenOever of NYU Grossman School of Medicine, examined golden hamstersone of the only lab animals that reliably develops COVID-19-like signs from SARS-CoV-2 infectionand found evidence that following nasal exposure the virus can infect the cells of the natural cardiac pacemaker unit, known as the sinoatrial node.

To study SARS-CoV-2s effects on pacemaker cells in more detail and with human cells, the researchers used advanced stem cell techniques to induce human embryonic stem cells to mature into cells closely resembling sinoatrial node cells. They showed that these induced human pacemaker cells express the receptor ACE2 and other factors SARS-CoV-2 uses to get into cells and are readily infected by SARS-CoV-2. The researchers also observed large increases in inflammatory immune gene activity in the infected cells.

The teams most surprising finding, however, was that the pacemaker cells, in response to the stress of infection, showed clear signs of a cellular self-destruct process called ferroptosis, which involves accumulation of iron and the runaway production of cell-destroying reactive oxygen molecules. The scientists were able to reverse these signs in the cells using compounds that are known to bind iron and inhibit ferroptosis.

This finding suggests that some of the cardiac arrhythmias detected in COVID-19 patients could be caused by ferroptosis damage to the sinoatrial node, said co-senior author Dr. Robert Schwartz, an associate professor of medicine in the Division of Gastroenterology and Hepatology at Weill Cornell Medicine and a hepatologist at NewYork-Presbyterian/Weill Cornell Medical Center.

Although in principle COVID-19 patients could be treated with ferroptosis inhibitors specifically to protect sinoatrial node cells, antiviral drugs that block the effects of SARS-CoV-2 infection in all cell types would be preferable, the researchers said.

The researchers plan to continue to use their cell and animal models to investigate sinoatrial node damage in COVID-19and beyond.

There are other human sinoatrial arrhythmia syndromes we could model with our platform, said co-senior author Dr. Todd Evans, the Peter I. Pressman M.D. Professor of Surgery and associate dean for research at Weill Cornell Medicine. And, although physicians currently can use an artificial electronic pacemaker to replace the function of a damaged sinoatrial node, theres the potential here to use sinoatrial cells such as weve developed as an alternative, cell-based pacemaker therapy.

Many Weill Cornell Medicine physicians and scientists maintain relationships and collaborate with external organizations to foster scientific innovation and provide expert guidance. The institution makes these disclosurespublic to ensure transparency. For this information, see profiles for Dr. Todd Evans, and Dr. Robert Schwartz.

See the original post:
Are COVID-19-Linked Arrhythmias Caused by Viral Damage to the Heart's Pacemaker Cells? - Weill Cornell Medicine Newsroom

Recommendation and review posted by Bethany Smith